<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article">
  <?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.1.0//EN//XML?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName art510.dtd?>
  <?SourceDTD.Version 5.1.0?>
  <?ConverterInfo.XSLTName elsevier2nlmx2.xsl?>
  <?ConverterInfo.Version 2?>
  <?origin publisher?>
  <?FILEmeta_EXG8837 xml ?>
  <?FILEmain xml ?>
  <?FILEgr1 jpg ?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Exp Gerontol</journal-id>
      <journal-title-group>
        <journal-title>Experimental Gerontology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0531-5565</issn>
      <issn pub-type="epub">1873-6815</issn>
      <publisher>
        <publisher-name>Elsevier Science</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3070802</article-id>
      <article-id pub-id-type="pmid">21112383</article-id>
      <article-id pub-id-type="publisher-id">EXG8837</article-id>
      <article-id pub-id-type="doi">10.1016/j.exger.2010.11.032</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Chronic mild cerebrovascular dysfunction as a cause for Alzheimer's disease?</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Humpel</surname>
            <given-names>Christian</given-names>
          </name>
          <email>christian.humpel@i-med.ac.at</email>
          <xref rid="cr0005" ref-type="corresp">&#x204E;</xref>
        </contrib>
      </contrib-group>
      <aff id="af0005">Laboratory of Psychiatry and Exp. Alzheimers Research, Department of Psychiatry and Psychotherapy, Innsbruck Medical University, Austria</aff>
      <author-notes>
        <corresp id="cr0005"><label>&#x204E;</label>Dep. of Psychiatry and Psychotherapy, Anichstr. 35, A-6020 Innsbruck, Austria. Tel.: +43 512 504 23712; fax: +43 512 504 23713. <email>christian.humpel@i-med.ac.at</email></corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <month>4</month>
        <year>2011</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="ppub"/>. -->
      <pub-date pub-type="ppub">
        <month>4</month>
        <year>2011</year>
      </pub-date>
      <volume>46</volume>
      <issue>4</issue>
      <fpage>225</fpage>
      <lpage>232</lpage>
      <history>
        <date date-type="received">
          <day>15</day>
          <month>7</month>
          <year>2010</year>
        </date>
        <date date-type="rev-recd">
          <day>17</day>
          <month>11</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>19</day>
          <month>11</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xC2;&#xA9; 2011 Elsevier Inc.</copyright-statement>
        <copyright-year>2010</copyright-year>
        <copyright-holder>Elsevier Inc.</copyright-holder>
        <license>
          <license-p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Alzheimer's disease (AD) is a progressive chronic disorder and is characterized by &#x3B2;-amyloid plaques and angiopathy, tau pathology, neuronal cell death, and inflammatory responses. The reasons for this disease are not known. This review proposes the hypothesis that a chronic mild longlasting cerebrovascular dysfunction could initiate a cascade of events leading to AD. It is suggested that (vascular) risk factors (e.g. hypercholesterolemia, type 2 diabetes, hyperhomocysteinemia) causes either damage of the cerebrovascular system including silent strokes or causes dysregulation of beta-amyloid clearance at the blood-brain barrier resulting in increased brain beta-amyloid. A cascade of subsequent downstream events may lead to disturbed metabolic changes, and neuroinflammation and tau pathology. The role of NGF on the cell death of cholinergic neurons is discussed. Additional risk factors (e.g. acidosis, metals) contribute to plaque development.</p>
      </abstract>
      <abstract abstract-type="graphical">
        <title>Research Highlights</title>
        <p>&#x25BA; Hypothesis for development of Alzheimers disease. &#x25BA; Chronic mild vascular risk factors damage brain capillaries. &#x25BA; Dysregulation of beta-amyloid clearance at the blood-brain barrier. &#x25BA; Vascular dysfunction causes metabolic disturbances. &#x25BA; Downstream cascade causes inflammation, oxiditative stress and neurodegeneration.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Vascular system</kwd>
        <kwd>Alzheimer</kwd>
        <kwd>Vascular dementia</kwd>
        <kwd>Hypothesis</kwd>
        <kwd>Cascade</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="s0005">
      <label>1</label>
      <title>Alzheimers disease and other forms of dementia</title>
      <p>Sporadic Alzheimer's disease (AD) is a progressive chronic neurodegenerative disorder (at least 95% of all cases are non-genetic), and is characterized by severe beta-amyloid deposition (senile plaques and vascular angiopathy), tau-pathology, cell death of cholinergic neurons, microglial activation and inflammation. AD is the most aggressive form of dementia and is distinguished from other forms of dementia. The differentiation of vascular dementia (vaD) from AD has been based on evidence of a cerebrovascular disorder (<xref rid="bb0495" ref-type="bibr">Roth, 1955</xref>). However, pure cases of vaD without neurodegenerative changes are very rare and autopsy of cases clinically diagnosed as vaD showed that they had pathological signs for AD (<xref rid="bb0500" ref-type="bibr">Sadowski et al., 2004</xref>). In addition, mild cognitive impairment (MCI) has been defined as the earliest form of dementia, which partly converts into AD (approx. 15% to 30% per year). Two additional forms of degenerative non-reversible forms of dementia have been described, Lewy Body dementia and frontotemporal dementia, which can be distinguished from AD and vaD. In addition, other non-specific forms of dementia are seen during, for example, HIV, Parkinson's disease, or alcohol-related diseases. Among all forms of dementia, AD is the most frequent pathological finding (approx. 60%), followed by vaD (approx. 15%), Lewy body dementia (approx. 15%), frontotemporal dementia (approx. 5%), and other degenerative forms of dementia (<xref rid="bb0210 bb0245" ref-type="bibr">Gearing et al., 1995; Heinemann and Zerr, 2007</xref>). In addition, the term vascular cognitive impairment (VCI) is used to describe individuals with significant cognitive impairments produced by cerebrovascular disease (CVD) (<xref rid="bb0045" ref-type="bibr">Barone et al., 2009</xref>).</p>
    </sec>
    <sec id="s0010">
      <label>2</label>
      <title>Cerebrovascular abnormalities in AD</title>
      <p>Possibly the most important changes arguing for a vascular hypothesis in AD are the cerebral bloodflow (CBF) measurements in MCI and the fluorodeoxyglucose positron emission tomography (FDG-PET) studies measuring glucose uptake. FDG-PET has shown decreased glucose metabolism in the medial temporal and parietal lobes of those with the APOE4 gene many decades prior to the typical age of AD onset, and that AD can be prognosed in cognitively intact persons showing reduced glucose uptake (<xref rid="bb0400" ref-type="bibr">Mosconi et al., 2010</xref>). In addition, arterial spin labeling (<xref rid="bb0015" ref-type="bibr">Alsop et al., 2010</xref>), SPECT (<xref rid="bb0630" ref-type="bibr">Varma et al., 2002</xref>) or H(2)15O positron emission tomography (<xref rid="bb0280" ref-type="bibr">Ishii et al., 2000</xref>) provided a reflection of CBF activity in cognitively intact people who later converted to AD.</p>
      <p>A number of cerebrovascular abnormalities have been described in AD brains: decreased microvascular density, basement membrane thickening, endothelial and pericyte damage, diminished glucose transport across the blood-brain barrier (BBB), vessels that express inflammatory markers, perivascular fibrosis, capillaries with fewer branches, atrophic vessels, changes in vessel diameter, accumulation of e.g. collagen, atheriosclerotic plaques, cerebral amyloid angiopathy, microglial activation in degenerating endothelial cells or thrombotic lesions (<xref rid="bb0185" ref-type="bibr">Farkas and Luiten, 2001</xref>). It is very difficult to say if these changes are an initial cause for development of AD or if these changes occur in late stages of the disease. Anyhow, there is clear evidence that these cerebrovascular abnormalities result in dysfunctional influx of toxic compounds into the brain or result in enhanced storage or reduced efflux of metabolic waste products in the brain, or result in dysregulated oxygen or glucose supply or last not least in a dsyfunctional clearance of different compounds at the BBB.</p>
    </sec>
    <sec id="s0015">
      <label>3</label>
      <title>Risk factors for AD and vaD</title>
      <p>It is well known that less than 2.5% of all AD cases have a genetic origin, but the majority of AD is a sporadic form and the major risk factor is age (&gt;&#xA0;60&#xA0;years). The causes for this sporadic AD are yet unknown, but several risk factors may trigger this disease. There is increasing evidence that vascular risk factors contribute to the pathogenesis of AD (<xref rid="bb0310 bb0135 bb0140 bb0130 bb0270 bb0705 bb0260" ref-type="bibr">Kudo et al., 2000; de la Torre and Mussivand, 1993; De la Torre and Stefano, 2000; De la Torre, 2002; Iadecola, 2004; Zlokovic, 2005; Humpel and Marksteiner, 2005</xref>). In fact, a cerebrovascular hypoperfusion caused by decreased cerebral blood flow, lowered metabolic rates of glucose and oxygen could be one of the initial events in AD (<xref rid="bb0070 bb0145 bb0155 bb0185 bb0270" ref-type="bibr">Breteler, 2000; Dede et al., 2007; Deschaintre et al., 2009; Farkas and Luiten, 2001; Iadecola, 2004</xref>). AD and vaD may share common risk factors, which indicate that their pathogenic mechanism could be related (<xref rid="bb0130" ref-type="bibr">De la Torre, 2002</xref>). It is hypothesized that neurodegeneration in AD may arise from a chronic mild cerebrovascular dysregulation caused by continuous exposure to the risk factors over years (<xref rid="bb0260" ref-type="bibr">Humpel and Marksteiner, 2005</xref>), which precedes hypoperfusion (<xref rid="bb0140 bb0270" ref-type="bibr">De la Torre and Stefano, 2000; Iadecola, 2004</xref>). Evidence comes from epidemiological studies that these risk factors are (<xref rid="bb0485 bb0130 bb0705 bb0160" ref-type="bibr">Rocchi et al., 2009; De la Torre, 2002; Zlokovic, 2005; Engelberg, 2004</xref>): old age, atherosclerosis, stroke, diabetes, homocysteine, hypertension, hyperlipidemia, head injury, transient silent strokes, high serum viscosity, thrombogenic factors, cardiac disease, the apolipoprotein E4 allele, smoking, alcohol consumption, high cholesterol, fat food, reduced vitamin B12 uptake, high blood pressure, high fibrinogen levels, hormonal dysregulation, depression, and others. It is evident that several of these risk factors are vascular risk factors.</p>
      <sec id="s0020">
        <label>3.1</label>
        <title>Hyperhomocysteinemia</title>
        <p>It is well established that elevated plasma levels of the amino acid homocysteine increase the risk for atherosclerosis, stroke, myocardial infarction, and AD (<xref rid="bb0205 bb0180 bb0190 bb0560 bb0465 bb0620" ref-type="bibr">Gallucci et al., 2004; Faraci, 2003; Flicker et al., 2004; Skurk and Walsh, 2004; Ravaglia et al., 2005; Troen, 2005</xref>). It has been reported that plasma homocysteine levels &gt;&#xA0;15&#xA0;&#x3BC;M increase the risk for vaD and AD (<xref rid="bb0100 bb0385 bb0535 bb0350" ref-type="bibr">Clarke et al., 1998; McIlroy et al., 2002; Seshadri et al., 2002; Luchsinger et al., 2004</xref>). In humans the effective concentration results from total levels of homocysteine and its oxidation product disulfide homocysteine (<xref rid="bb0345" ref-type="bibr">Lipton et al., 1997</xref>). Hyperhomocysteinemia induces endothelial damage, mitochondrial disintegration, swelling of pericytes, basement membrane thickening and perivascular detachment (<xref rid="bb0645 bb0295 bb0620" ref-type="bibr">Weir and Molloy, 2000; Kim et al., 2002; Troen, 2005</xref>), pathologies are also seen in vaD and AD. The intracellular effects of homocysteine are very divergent: it induces, for example, caspase-8 and subsequent apoptosis, it stimulates monocyte chemoattractant protein-1/interleukin-8 and subsequent inflammation, and it enhances oxidative stress (via activation of different oxidases), inhibits endothelial nitric oxide synthetase, and generates peroxynitrite with subsequent cell death (<xref rid="bb0180 bb0320 bb0560" ref-type="bibr">Faraci, 2003; Lee et al., 2004; Skurk and Walsh, 2004</xref>). Furthermore, homocysteine decreases capillary endothelial nitric oxide synthetase (<xref rid="bb0180" ref-type="bibr">Faraci, 2003</xref>) and glucose transporter and transiently changes different cell adhesion molecules (<xref rid="bb0320" ref-type="bibr">Lee et al., 2004</xref>). Homocysteine directly induces cell death of cerebrocortical neurons involving NMDA (<xref rid="bb0345" ref-type="bibr">Lipton et al., 1997</xref>). Chronic hyperhomocysteinemia induced by methionin administration enhanced lipid peroxidaton and decreased glutathione, suggesting the involvement of oxidative stress (<xref rid="bb0050" ref-type="bibr">Baydas et al., 2005</xref>). These dysfunctions are accompanied by cognitive impairment and can be counteracted by the antioxidant melatonin (<xref rid="bb0050" ref-type="bibr">Baydas et al., 2005</xref>).</p>
      </sec>
      <sec id="s0025">
        <label>3.2</label>
        <title>Hypercholesterolemia</title>
        <p>Cholesterol is increasingly recognized to play a major role in the pathogenesis of AD (<xref rid="bb0455 bb0650 bb0680" ref-type="bibr">Raffai and Weisgraber, 2003; Wellington, 2004; Wolozin, 2004</xref>). This is based on four lines of investigation: (1) the lipoprotein ApoE4 coordinates the mobilization and redistribution of cholesterol in the brain and affects the age of onset, (2) intracellular cholesterol stimulates &#x3B3;-secretase and amyloid-precursor-protein (APP)/&#x3B2;-amyloid processing, (3) cholesterol-lowering drugs (statins) reduce the prevalence of AD and (4) elevated plasma cholesterol in midlife is associated with an increased risk for AD. Interestingly, rabbits fed with a 2% cholesterol diet display an accumulation of intracellular immunolabeled &#x3B2;-amyloid after 4 to 8&#xA0;weeks (<xref rid="bb0585" ref-type="bibr">Sparks et al., 1994</xref>) and hypercholesterolemia accelerates the amyloid pathology in a transgenic mouse model (<xref rid="bb0470 bb0545" ref-type="bibr">Refolo et al., 2000; Shie et al., 2002</xref>). Cholesterol does not pass the BBB and is synthesized locally in the brain and degraded to 24-hydroxy-cholesterol, which is transported outside the brain into the bloodstream. Cholesterol regulates &#x3B3;-secretase with enhanced processing of &#x3B2;-amyloid(1&#x2013;42). It is hypothesized that a breakdown of the BBB causes influx of cholesterol, with subsequent activation of &#x3B3;-secretase and enhanced &#x3B2;-amyloid(1&#x2013;42) production. These findings are consistent with the concept that AD is a dietary-fat induced phenotype of vascular dementia and accumulation of beta-amyloid-lipoprotein complexes may be an amplifier of dietary induced inflammation (<xref rid="bb0595" ref-type="bibr">Takechi et al., 2010</xref>).</p>
      </sec>
      <sec id="s0030">
        <label>3.3</label>
        <title>Hyperglycemia and insulin depletion</title>
        <p>Approximately 40&#x2013;50% of elderly people have an impaired glucose metabolism or type 2 diabetes and hyperglycemia is a risk for AD (<xref rid="bb0290 bb0095 bb0435" ref-type="bibr">Kalaria, 2009; Carlsson, 2010; Ott et al., 1999</xref>). Inded, PET studies demonstrated a reduced glucose uptake in AD patients (<xref rid="bb0170" ref-type="bibr">Erol, 2008</xref>). Hyperglycemia has disruptive effects on the brain and markedly affects cognition and memory (<xref rid="bb0065" ref-type="bibr">Brands et al., 2004</xref>). Hyperglycemia leads to increased levels of glucose in the brain, by which excess glucose is converted into sorbitol and fructose, which influences several intracellular cascades. Elevated glucose is also associated with formation of toxic advanced glycation end (AGE) products, reactive oxygen species (ROS), or hyperhomocysteinemia. Hyperglycemia is also associated with both structural and functional alterations in the cerebral vascular system. Cerebral blood flow has been reported to be decreased in diabetes and thus increasing risk of &#x201C;silent strokes.&#x201D; Longitudinal studies showed an association between insulin resistance and AD (<xref rid="bb0170" ref-type="bibr">Erol, 2008</xref>). Insulin regulates the metabolism of &#x3B2;-amyloid and tau and dysfunctional insulin signaling has been linked to oxidative stress and mitochondrial dysfunction, resulting in disturbances of cellular glucose, acetylcholine, cholesterol and ATP levels, impaired membrane function, accumulation of &#x3B2;-amyloid and tau hyperphosporylation (<xref rid="bb0170" ref-type="bibr">Erol, 2008</xref>). An interesting in vivo mouse model shows hyperphosphorylated tau after streptozotocin-induced insulin deficiency (<xref rid="bb0105" ref-type="bibr">Clodfelder-Miller et al., 2006</xref>).</p>
      </sec>
      <sec id="s0035">
        <label>3.4</label>
        <title>Chronic alcoholism</title>
        <p>Alcohol may be a risk factor for AD because of similarities between alcoholic dementia and AD. Epidemiologic studies have investigated the relationship between alcohol and AD, however, there is clear indication that light to moderate alcohol intake (1&#x2013;3 drinks per day; &lt;&#xA0;20 g alcohol per day) was significantly associated with a lower risk for AD (<xref rid="bb0020 bb0625" ref-type="bibr">Anstey et al., 2009; Tyas, 2001</xref>). The neuroprotective effect of antioxidant properties of wine polyphenols may be important in preventing AD (<xref rid="bb0445" ref-type="bibr">Pinder and Sandler, 2004</xref>). Heavy drinking is a risk factor for most stroke subtypes, while regular light to moderate drinking seemed to be associated with a decreased risk for ischemic strokes (<xref rid="bb0325" ref-type="bibr">Letenneur, 2004</xref>). It cannot be excluded that heavy drinking may account for vascular damage in the brain and may contribute to the development of AD .</p>
      </sec>
    </sec>
    <sec id="s0040">
      <label>4</label>
      <title>Beta-Amyloid in AD and the vascular connection</title>
      <p>So far, the &#x3B2;-amyloid cascade is the most prominent hypothesis for development of AD (<xref rid="bb0525 bb0040 bb0605 bb0675 bb0360 bb0510" ref-type="bibr">Selkoe, 1998; Atwood et al., 2003; Tanzi et al., 2004; Wirths et al., 2004; Marchesi, 2005; Schroeder and Koo, 2005</xref>) and is thought to be the primary event that triggers the pathological cascade in AD (<xref rid="bb0525" ref-type="bibr">Selkoe, 1998</xref>), although the findings in support of the amyloid hypothesis have become questionable and controversial (<xref rid="bb0480" ref-type="bibr">Robakis, 2010</xref>). The amyloid-precursor protein (APP) is cleaved by secretases into &#x3B2;-amyloid peptides (40, 42, or 43 amino acids), and these peptides aggregate under certain conditions and are deposited as &#x3B2;-amyloid plaques. It is hypothesized that the accumulation of &#x3B2;-amyloid in the brain causes the AD pathology and a dysbalance between &#x3B2;-amyloid production and clearance results in other hallmarks of the disease. The &#x3B2;-amyloid cascade hypothesis (<xref rid="bb0240 bb0600" ref-type="bibr">Hardy and Selkoe, 2002; Tanzi and Bertram, 2005</xref>) favors the model that insoluble fibrillar &#x3B2;-amyloid triggers the neuronal degeneration. Evidence is now accumulating that soluble activated monomers, soluble oligomers (dimer, trimer, tetramer), and protofibrils could be responsible for triggering the pathology in AD (<xref rid="bb0640 bb0090" ref-type="bibr">Walsh et al., 2002; Canevari et al., 2004</xref><bold>).</bold> The exact mechanism by which &#x3B2;-amyloid induces cell death is not known, but the &#x201C;channel hypothesis&#x201D; suggests that certain fibrillar forms of the peptide cause neurodegeneration by forming ion channels that are generally large, voltage independent, and relatively poor selective (<xref rid="bb0675 bb0360" ref-type="bibr">Wirths et al., 2004; Marchesi, 2005</xref>). Soluble &#x3B2;-amyloid levels in the cortex correlate with the degree of synaptic loss in dementia, and it becomes more and more clear that AD is primarily caused by dysfunction of nerve axons and synapses (<xref rid="bb0530" ref-type="bibr">Selkoe, 2002</xref>). In AD, axonal degeneration may depend on &#x3B2;-amyloid levels, but not on plaque deposition, which means that nerve damage occurs before deposition of plaques.</p>
      <p>&#x3B2;-amyloid is present in the brain and in the blood and is transported through the BBB via two important receptor transport systems: the receptor for advanced glycosylation end products (RAGE) and low-density lipoprotein-related protein (LRP) (<xref rid="bb0605 bb0700" ref-type="bibr">Tanzi et al., 2004; Zlokovic, 2004</xref>). The influx of &#x3B2;-amyloid from blood into brain is mediated via RAGE, while the efflux from brain into blood is mediated via LRP (<xref rid="bb0605 bb0700" ref-type="bibr">Tanzi et al., 2004; Zlokovic, 2004</xref>). This clearance from brain to blood is of pivotal importance for the regulation of &#x3B2;-amyloid levels in the brain (<xref rid="bb0605 bb0700" ref-type="bibr">Tanzi et al., 2004; Zlokovic, 2004</xref>) and a dysregulation of the BBB contributes to enhanced &#x3B2;-amyloid levels in the brain. Under specific conditions (high ApoE4, low pH, metals, and dysfunctional clearance) the &#x3B2;-amyloid (1&#x2013;42) peptide may aggregate in the brain.</p>
      <p>A very high percentage (70%&#x2013;90%) of AD patients show amyloid pathology in their vessels, which narrow the vessels and produce hypoperfusion (<xref rid="bb0565 bb0185 bb0125 bb0235" ref-type="bibr">Smith and Greenberg, 2009; Farkas and Luiten, 2001; Cullen et al., 2006; Hardy and Cullen, 2006</xref>). This cerebral amyloid angiopathy can result in hemorrhagic and (possibly) ischemic forms of stroke (<xref rid="bb0565 bb0025 bb0230 bb0575 bb0060" ref-type="bibr">Smith and Greenberg, 2009; Armstrong, 2006; Haglund et al., 2006; Soffer, 2006; Boscolo et al., 2007</xref>). The cerebral amyloid angiopathy is common in AD and is also associated with cerebral atheriosclerosis (<xref rid="bb0185 bb0130 bb0030" ref-type="bibr">Farkas and Luiten, 2001; de la Torre, 2002; Attems et al., 2004</xref>) and with the development of cognitive deficits (<xref rid="bb0610 bb0580" ref-type="bibr">Thal et al., 2003; Solfrizzi et al., 2004</xref>). As a consequence of cerebrovascular dysfunction the breakdown of the BBB may occur. This breakdown may have several effects on neurons, such as cell death after influx of excitotoxic amino acids (e.g. glutamate) or enhanced APP expression after cholesterol influx. In addition, an enhanced influx of blood-derived serum albumin into the brain is seen after BBB disrupture and may induce neurodegeneration (<xref rid="bb0405" ref-type="bibr">Moser and Humpel, 2007</xref>).</p>
    </sec>
    <sec id="s0045">
      <label>5</label>
      <title>Tauopathies, neurodegeneration, AD and vaD</title>
      <p>Tau protein is a microtubule-associated protein that is highly expressed in neurons in the brain. Tau is enriched in axons, where it directly binds to microtubuli. In AD tau is hyperphosphorylated at a variety of serine and threonine residues and loses its ability to bind to microtubuli. Such abnormal hyperphosphorylated tau is a major event involved in the formation of paired helical neurofibrillary tangles in the AD brain (<xref rid="bb0355 bb0590 bb0570 bb0275" ref-type="bibr">Mandelkow and Mandelkow, 1998; Spillantini and Goedert, 1998; Smith et al., 2002; Iqbal et al., 2005</xref>). An imbalance between protein kinases and phosphatases may play a role in hyperphosphorylation. Interestingly, it has become apparent that tau deposits are frequently observed in the abscence of amyloid plaques, such as e.g. corticobasal degeneration, Pick disease or progressive supranuclear palsy (<xref rid="bb0590" ref-type="bibr">Spillantini and Goedert, 1998</xref>). Most taupathies are sporadic diseases but some are familial. These findings suggest that neurofibrillary tangles develop independent of &#x3B2;-amyloid. Tau pathology in AD is almost entirely limited to nerve cells, while in other tauopathies both nerve cells and glial cells are affected (<xref rid="bb0590" ref-type="bibr">Spillantini and Goedert, 1998</xref>). In addition, enhanced tau is a diagnostic marker in cerebrospinal fluid for different forms of neurodegeneration (e.g. Creutzfeldt Jacobs disease).</p>
      <p><xref rid="bb0275" ref-type="bibr">Iqbal et al. (2005)</xref> have developed the &#x201C;Metabolic/Signal Transduction Hypothesis&#x201D;. It is assumed that AD and other tauopathies require a genetic predisposition (e.g. ApoE) and are triggered by a variety of environmental (risk) factors (e.g. which alter the membrane fluidity). It is suggested that an imbalance of protein kinases (e,g, cdk5, glycogen synthase kinase-3, CaM kinase II, protein kinase A) and/or phosphatases (e.g. PP-2A or PP-1) may lead to an abnormal hyperphosphorylation of tau and subsequently to formation of neurofibrillary tangles in the brain. There are indications that also vascular risk factor may play a role in tau pathology, since e.g. a decreased membrane fluidity by cholesterol could be one event leading to an imbalance in this system. In addition a decreased glucose metabolism/uptake might lead to the abnormal hyperphosphorylation of tau through a decrease in its O-GlcNAcylation (<xref rid="bb0275" ref-type="bibr">Iqbal et al., 2005</xref>). Finally, recently it has been shown that application of truncated tau to the basolateral (brain) side of the BBB causes damage of the BBB involving pro-inflammatory cytokines released from microglia (<xref rid="bb0300" ref-type="bibr">Kovac et al., 2009</xref>).</p>
    </sec>
    <sec id="s0050">
      <label>6</label>
      <title>The neurovascular unit, cholinergic neurons and NGF</title>
      <p>The neurovascular unit (NVU) defines the cellular interaction between brain capillary endothelial cells (forming the BBB), the astrocytic end feet, and neuronal axons (<xref rid="bb0270" ref-type="bibr">Iadecola, 2004</xref>). Astrocytes are involved in neuronal energy metabolism and synapse function (<xref rid="bb0270" ref-type="bibr">Iadecola, 2004</xref>) and neuronal processes are closely associated with cerebral blood vessels (<xref rid="bb0270" ref-type="bibr">Iadecola, 2004</xref>). Interestingly, nerve terminals from the cholinergic neurons of the basal nucleus of Meynert interact with astrocytic end feet of the BBB via muscarinic acetylcholine receptors (<xref rid="bb0635 bb0185" ref-type="bibr">Vaucher and Hamel, 1995; Farkas and Luiten, 2001</xref>). Thus the NVU provides a direct link between the cerebrovascular system and cholinergic neurons in the brain. Since the NVU provides the first line of defense against deleterious effects of cerebral ischemia and other forms of injury (<xref rid="bb0270" ref-type="bibr">Iadecola, 2004</xref>), the NVU may display a very sensitive (pH dependent) link to the brain. In fact, conditioned medium collected from microvessels of AD patients has been shown to kill neurons in vitro, pointing to selective neurotoxic factors derived from brain capillary endothelial cells (<xref rid="bb0225" ref-type="bibr">Grammas et al., 1999</xref>). This is in agreement with our own study, where we found that rat primary capillary endothelial cells secreted factors into the medium, which killed cholinergic neurons (<xref rid="bb0410" ref-type="bibr">Moser et al., 2004</xref>).</p>
      <p>In AD a marked reduction of cholinergic neurons in the basal forebrain (septum and nucleus basalis of Meynert) is found in advanced stages (<xref rid="bb0665 bb0670" ref-type="bibr">Whitehouse et al., 1983; Wilcock et al., 1982</xref>), which leads to the cholinergic hypothesis in AD (<xref rid="bb0200 bb0265" ref-type="bibr">Francis et al., 1999; Humpel and Weis, 2002</xref>). Cholinergic cell loss directly correlates with cognitive decline and a lack of acetylcholine is a hallmark in dementia and AD. It is not known, why these cholinergic neurons die, but it seems possible that the direct interaction with the cerebrovascular system may contribute to cholinergic decline. In fact, damage of the NVU may result in degeneration of nerve terminals and subsequent retrograde cell death of cholinergic neurons. However, neurodegeneration in AD also results in dysregulation of other neurotransmitter systems in the brain, such as serotonine, noradrenaline, or glutamate.</p>
      <p>Among all growth factors, nerve growth factor (NGF) is the most potent growth factor to counteract cell death of cholinergic neurons in vitro and in vivo (<xref rid="bb0615 bb0330" ref-type="bibr">Thoenen and Barde, 1980; Levi-Montalcini, 1987</xref>). In fact NGF was thought to play a role in the development of AD, but transgenic NGF knockout mice did not show an AD pathology. However, NGF was considered to be a candidate for treating AD and purified mouse NGF was infused in some AD patients (<xref rid="bb0520" ref-type="bibr">Seiger et al., 1993</xref>). Interestingly, NGF is upregulated in brains of AD patients (<xref rid="bb0175" ref-type="bibr">Fahnestock et al., 2001</xref>) and in cerebrospinal fluid (<xref rid="bb0250" ref-type="bibr">Hock et al., 2000</xref>), while the high-affinity NGF receptor trkA is downregulated (<xref rid="bb0420 bb0115" ref-type="bibr">Mufson et al., 2002; Counts et al., 2004</xref>). It can be explained that enhanced cortical (target-derived) NGF is enhanced but cannot be transported to neuronal somata, because the axonal transport is destructed and the receptors are not functional (<xref rid="bb0415" ref-type="bibr">Mufson et al., 1999</xref>). Recent evidence shows that the precursor form of NGF (pro-NGF) and not mature NGF is liberated in the brain, and its processing is regulated by plasmin, which is under control of plasminogen activator (<xref rid="bb0080" ref-type="bibr">Bruno et al., 2009</xref>). In AD it has been suggested that &#x3B2;-amyloid induced microglial activation would generate oxidative stress (iNOS, peroxynitrite), which (1) inhibits processing of pro-NGF to mature NGF and (2) activates matrix-metalloproteinase-9 and induces degradation of mature NGF. This event results in drastic reduction of the bioactivity of NGF for the cholinergic neurons and may further induce neuronal cell death (<xref rid="bb0080" ref-type="bibr">Bruno et al., 2009</xref>).</p>
    </sec>
    <sec id="s0055">
      <label>7</label>
      <title>Silent strokes and acidosis</title>
      <p>Cerebrovascular disease and ischemic brain injury secondary to cardiovascular diseases are common causes of dementia and cognitive decline in the elderly (<xref rid="bb0165" ref-type="bibr">Erkinjuntti et al., 2004</xref>). Territorial infarct, old age, and low educational level were identified as predictors of cognitive disorders after stroke (<xref rid="bb0460" ref-type="bibr">Rasquin et al., 2004</xref>). Stroke may account for as many as 50% AD cases in old age (<xref rid="bb0285" ref-type="bibr">Kalaria, 2000</xref>), and it is known that ischemic events induce APP, &#x3B2;-amyloid, and tau pathology (<xref rid="bb0285" ref-type="bibr">Kalaria, 2000</xref>). Approximately 35% of AD patients show autopsy-proven vascular infarcts and 60% show white matter lesions. There exists an association between stroke and AD that may be due to an underlying systemic vascular disease process or, alternatively, due to the additive effects of stroke and AD pathologic features, leading to an earlier age at onset of disease (<xref rid="bb0255" ref-type="bibr">Honig et al., 2003</xref>). Several longitudinal studies report an association between stroke and cognitive decline (<xref rid="bb0315 bb0340 bb0490 bb0690" ref-type="bibr">Langa et al., 2004; Linden et al., 2004; Roman, 2004; Zhou et al., 2004</xref>). Such small ischemic lesions (&#x201C;silent stroke&#x201D;, cortical microinfarcts; <xref rid="bb0305" ref-type="bibr">Kovari et al., 2007</xref>), which in isolation would not alter cognition, substantially aggravate dementia, indicating that cerebral ischemia may interact with AD pathology. It is now widely accepted that acidosis is an important component of the pathological event that leads to ischemic brain damage (<xref rid="bb0550 bb0555" ref-type="bibr">Siesjo, 1988, 1992</xref>). Acidosis is a result of either an increase in tissue CO<sub>2</sub> or an accumulation of acids produced by dysfunctional metabolism (<xref rid="bb0475" ref-type="bibr">Rehncrona, 1985</xref>). Moderate ischemia may cause a fall in tissue pH to around 6.6 without any morphological evidence of irreversible cell damage (<xref rid="bb0475" ref-type="bibr">Rehncrona, 1985</xref>). In severe ischemia, anaerobic glycolysis leads to accumulation of acids, for example, lactate, causing a decrease in pH to around 6.0 (<xref rid="bb0475" ref-type="bibr">Rehncrona, 1985</xref>) with strong signs of irreversible damage. We have recently shown that cholinergic neurons undergo cell death when the pH is lowered to a critical values of 6.8 (<xref rid="bb0450" ref-type="bibr">Pirchl et al., 2006</xref>). It is well known that acidosis enhances iron-catalyzed production of reactive oxygen species, probably by releasing iron from its binding to transferrin, ferritin, or other proteins (<xref rid="bb0335" ref-type="bibr">Li and Siesjo, 1997</xref>). It seems likely that the NVU is very sensitive for changes in pH and the interaction between vascular structures and cholinergic nerve fibers should be considered as a critical element in neurodegeneration, especially in the view of long-standing suggestions that vessels are lost in the aging brain.</p>
      <p>It is highly interesting to note that &#x3B2;-amyloid processing is markedly affected by low pH, which could link acidosis to AD. Lactate caused a dose-dependent increase in cellular &#x3B2;-amyloid immunoreactivity in hippocampal neurons but acidosis did not affect secretion of sAPP (<xref rid="bb0075" ref-type="bibr">Brewer, 1997</xref>). A marked Cu<sup>2+</sup> induced aggregation of &#x3B2;-amyloid emerged when the pH was lowered to 6.8, indicating that H<sup>+</sup> induced conformational changes unmask a metal-binding site on &#x3B2;-amyloid that mediates reversible assembly of the peptide that could have relevance for plaque deposition in AD (<xref rid="bb0035" ref-type="bibr">Atwood et al., 1998</xref>). &#x3B2;-amyloid(15&#x2013;22) controls aggregation of &#x3B2;-amyloid(1&#x2013;42) at acidic pH and its proteolytic activity at neutral pH (<xref rid="bb0380" ref-type="bibr">Matsunaga et al., 1994</xref>). Prolonged acidosis may in fact contribute to the dysregulation of &#x3B2;-amyloid and subsequent plaque deposition and cell death of cholinergic neurons. We have recently shown that under acidic conditions (pH 6.0&#xA0;+&#xA0;ApoE4) cholinergic neurons degenerate in brain slices that is accompanied by aggregated &#x3B2;-amyloid peptides (<xref rid="bb0375" ref-type="bibr">Marksteiner and Humpel, 2008</xref>).</p>
    </sec>
    <sec id="s0060">
      <label>8</label>
      <title>Inflammation and the vascular connection in AD and vaD</title>
      <p>Inflammation is an important trigger of neurodegeneration during aging (&#x201C;Inflammaging&#x201D;) (<xref rid="bb0195" ref-type="bibr">Franceschi et al., 2000</xref>) and considered as a major actor of neurodegeneration in AD. Inflammation is a potential target for AD therapy and anti-inflammatory drugs may delay AD (<xref rid="bb0440 bb0390" ref-type="bibr">Perry et al., 1995; Moore and O'Banion, 2002</xref>). In AD oxidation of DNA, proteins and fatty acids occur in different brain areas. Some of the oxidation products have been found in the neurofibrillary tangles and senile plaques (<xref rid="bb0370" ref-type="bibr">Markesbery and Carney, 1999</xref>) and these oxidative modifications are closely associated with an inflammatory process in the AD brain (<xref rid="bb0085" ref-type="bibr">Butterfield et al., 2002</xref>). Indeed, cholinergic neurons of the basal nucleus of Meynert are very sensitive for inflammatory insults (<xref rid="bb0655 bb0660" ref-type="bibr">Wenk et al., 2000, 2003</xref>). Chronic release of pro-inflammatory cytokines, such as interleukin-1beta, tumor-necrosis-factor alpha or transforming-growth factor-beta1, indicates a powerful role in inflammation, pathology and neuronal dysfunction associated with AD (<xref rid="bb0440 bb0220 bb0660" ref-type="bibr">Perry et al., 1995; Grammas and Ovase, 2002; Wenk et al., 2003</xref>). These inflammatory processes include activation of microglia and subsequent neuroinflammatory processes (<xref rid="bb0215" ref-type="bibr">Gonzalez-Scarano and Baltuch, 1999</xref>). However, again it is not clear if inflammation is a result of &#x3B2;-amyloid dysregulation (<xref rid="bb0390" ref-type="bibr">Moore and O'Banion, 2002</xref>) or if inflammation itself is the primary cause in initiation of AD. Inflammation of brain capillary endothelial cells may play a potent role, and it is well known that endothelial cells strongly respond to inflammatory stimuli (<xref rid="bb0410" ref-type="bibr">Moser et al., 2004</xref>) especially involving production of reactive oxygen species (<xref rid="bb0270" ref-type="bibr">Iadecola, 2004</xref>).</p>
    </sec>
    <sec id="s0065">
      <label>9</label>
      <title>Oxidative stress and mitochondrial failure in AD and vaD</title>
      <p>A rapidly growing body of evidence indicates that increased oxidative stress from reactive oxygen radicals is associated with increased glutamate activity (<xref rid="bb0055 bb0430 bb0120" ref-type="bibr">Beal, 1996; Olanow, 1993; Coyle and Puttfarcken, 1993</xref>). Oxidative damage induced by free radicals targets intracellular structures such as DNA, lipids, or proteins and these free radicals, generated through mitochondrial metabolism, can act as causative factors of abnormal function and cell death. These oxidative changes can arise from the normal aging process, head trauma, silent strokes, increased levels of heavy metals (iron, aluminum, and mercury), and possibly the aggregation of &#x3B2;-amyloid (<xref rid="bb0010" ref-type="bibr">Aliev et al., 2003</xref>). Interestingly, in human cerebral endothelial cells the endothelial barrier integrity is affected through activation of glutamate NMDA receptors resulting in loss of the cerebral endothelial barrier dysfunction (<xref rid="bb0540" ref-type="bibr">Sharp et al., 2003</xref>). In this respect, glutamate is also known to promote a breakdown of the BBB (<xref rid="bb0150" ref-type="bibr">Del Zoppo and Mabuchi, 2003</xref>). Some of the oxidation products have been found in the neurofibrillary tangles and senile plaques and these oxidative modifications are closely associated with an inflammatory process in the AD brain (<xref rid="bb0085" ref-type="bibr">Butterfield et al., 2002</xref>). Mitochondria are essential for generating the ATP for neurons, and a functional impairment results in neurodegeneration. Interestingly, vascular hypoperfusion induces dysfunction of mitochondria in AD with subsequent RNA oxidation, lipid peroxidation, or mitochondrial DNA deletion (<xref rid="bb0365 bb0425 bb0695" ref-type="bibr">Marcus et al., 1998; Nunomura et al., 1999; Zhu et al., 2004</xref>).</p>
    </sec>
    <sec id="s0070">
      <label>10</label>
      <title>Role of reactive astrocytes</title>
      <p>It has been assumed that reactive astrocytes could contribute to the pathomechanisms underlying AD by favoring oxidative neuronal damage (<xref rid="bb0515" ref-type="bibr">Schubert et al., 2001</xref>). Microglial cytokines, such as e.g. interleukin-1beta may, trigger production of apolipoprotein E and reactive astrocytes could promote the transformation of beta-amyloid into toxic forms (<xref rid="bb0515" ref-type="bibr">Schubert et al., 2001</xref>). Alternatively, it is well established that beta-amyloid peptides causes striking changes in astrocytes by activating astroglial calcium signaling (<xref rid="bb0005" ref-type="bibr">Abramov et al., 2004</xref>). These calcium signals were closely associated with transient acidification and generation of reactive oxygen species (ROS) and it was assumed that oxidative stress induced in reactive astrocytes may contribute to neuronal cell death (<xref rid="bb0005" ref-type="bibr">Abramov et al., 2004</xref>). Interestingly, it has been shown that astrocytic nitric oxide triggers hyperphosphorylation in hippocampal neurons (<xref rid="bb0505" ref-type="bibr">Saez et al., 2004</xref>).</p>
    </sec>
    <sec id="s0075">
      <label>11</label>
      <title>A common hypothesis &#x2014; what is the link?</title>
      <p>How do all these puzzle stones fit into one model? It is not clear, how AD is caused and it is not clear how the different forms of dementia fit into one model. Is vascular dementia another disease or is it an early stage of AD? Is mild cognitive impairment the earliest form of AD and of vascular dementia? Many researchers favor the &#x3B2;-amyloid cascade hypothesis, and think that a dysregulation of &#x3B2;-amyloid metabolism is the primary cause for AD. Other researchers believe that only tau may account for the disease without affecting the &#x3B2;-amyloid processing. Putting several evidence together, it seems possible that the aging of the cerebrovascular system may trigger the development of dementia: age is the most important risk factor and different vascular risk factors correlate with the development of dementia and with cognitive deficits.</p>
      <p>So far there is evidence that AD could be caused by two initial events (<xref rid="f0005" ref-type="fig">Fig.&#xA0;1</xref>): chronic mild exposure to (cardiovascular) risk factors over years causes (1) damage of the brain cerebrovascular system leading to metabolic disturbances in the brain or (2) a dysbalance of the clearance of &#x3B2;-amyloid from brain to blood or vice versa which may increase brain &#x3B2;-amyloid levels. A cascade of downstream events may lead to &#x3B2;-amyloid plaques and tau pathology. The risk factors may include e.g. hyperhomocysteinemia, hypercholesterolemia, type 2 diabetes or likely combinations.</p>
      <p>Pathway 1 (vascular): It is suggested that a vascular damage results in silent strokes and acidic conditions leading to several metabolic disturbances, such as enhanced influx of toxic compounds, or decreased efflux of metabolic waste and reduced energy supply (<xref rid="f0005" ref-type="fig">Fig.&#xA0;1</xref>). In parallel a damage of the sensitive NVU may occur. As a result of the damage of the NVU cholinergic synapses lose contact with the NVU. It seems likely that such an event may cause retrograde-induced axonal damage and subsequent cell death of cholinergic neurons (<xref rid="f0005" ref-type="fig">Fig.&#xA0;1</xref>). Such a loss of cholinergic neurons correlates with lack of acetylcholine in cortex and hippocampus, resulting in retrograde cell death of cholinergic neurons (<xref rid="f0005" ref-type="fig">Fig.&#xA0;1</xref>). The resulting microglial activation causes release of proinflammatory cytokines and oxdiative stress with production of radicals and finally reactive gliosis. It has been shown that this results in enhanced degradation of NGF and thus a decrease of NGF bioavailability for cholinergic neurons further induces neurodegeneration of cholinergic neurons.</p>
      <p>Pathway 2 (clearance): Yet unknown risk factors may damage the BBB and result in dysfunctional clearance of &#x3B2;-amyloid from brain to blood. Alternatively, peripheral blood-derived &#x3B2;-amyloid enters the brain (<xref rid="f0005" ref-type="fig">Fig.&#xA0;1</xref>). Such a dysfunctional clearance may result in enhanced &#x3B2;-amyloid levels in the brain tissue (<xref rid="f0005" ref-type="fig">Fig.&#xA0;1</xref>). Different risk factors, such as metals (copper, zink), reduced pH (&lt;&#xA0;6.8), dysfunctional transport or degradation of &#x3B2;-amyloid induce aggregation of &#x3B2;-amyloid resulting in plaque deposition (<xref rid="f0005" ref-type="fig">Fig.&#xA0;1</xref>). As a cause of either vascular damage and/or &#x3B2;-amyloid dysfunctional clearance, deposition of &#x3B2;-amyloid in vessels (angiopathy) may occur (<xref rid="f0005" ref-type="fig">Fig.&#xA0;1</xref>).</p>
      <p>Pathway 3 (Tau pathology). It is suggested that the metabolic disturbances cause an imbalance of specific protein kinases and phosphatases. This dysregulation causes abnormal tau phosphorylation and finally formation of paired helical filaments, the typical tau pathology. The abnormal tau pathology may further contribute to cholinergic cell death. It is not fully clear if &#x3B2;-amyloid plaques may directly induce tau pathology.</p>
      <p>It seems possible that the different stages in dementia are defined as the extent of damage of the cerebrovascular system and all subsequent events in the brain. However, it cannot be excluded that the &#x201C;final link&#x201D; is still missing, which may favor another, or a modified, hypothesis. Recently, it has been proposed that the blood-clotting factor fibrinogen could be one of the &#x201C;missing links&#x201D; of vascular and AD pathologies (<xref rid="bb0110 bb0685" ref-type="bibr">Cortes-Canteli et al., 2010; Wood, 2010</xref>).</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="bb0005">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abramov</surname>
              <given-names>A.Y.</given-names>
            </name>
            <name>
              <surname>Canevari</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Duchen</surname>
              <given-names>M.R.</given-names>
            </name>
          </person-group>
          <article-title>Calcium signals induced by amyloid beta peptide and their consequences in neurons and astrocytes in culture</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>1742</volume>
          <year>2004</year>
          <fpage>81</fpage>
          <lpage>87</lpage>
          <pub-id pub-id-type="pmid">15590058</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0010">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aliev</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Obrenovich</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>de la Torre</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Perry</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Role of vascular hypoperfusion-induces oxidative stress and mitochondria failure in the pathogenesis of Alzheimer's disease</article-title>
          <source>Neurotox. Res.</source>
          <volume>5</volume>
          <year>2003</year>
          <fpage>491</fpage>
          <lpage>504</lpage>
          <pub-id pub-id-type="pmid">14715433</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0015">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alsop</surname>
              <given-names>D.C.</given-names>
            </name>
            <name>
              <surname>Dai</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Grossman</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Detre</surname>
              <given-names>J.A.</given-names>
            </name>
          </person-group>
          <article-title>Arterial spin labeling blood flow MRI: its role in the early characterization of Alzheimer's disease</article-title>
          <source>J. Alzheimers Dis.</source>
          <volume>20</volume>
          <year>2010</year>
          <fpage>871</fpage>
          <lpage>880</lpage>
          <pub-id pub-id-type="pmid">20413865</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0020">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Anstey</surname>
              <given-names>K.J.</given-names>
            </name>
            <name>
              <surname>Mack</surname>
              <given-names>H.A.</given-names>
            </name>
            <name>
              <surname>Cherubin</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Alcohol consumption as a risk factor fro dementia and cognitive decline: meta-analysis of prospective studies</article-title>
          <source>Am. J. Geriatr. Psychiatry</source>
          <volume>17</volume>
          <year>2009</year>
          <fpage>542</fpage>
          <lpage>555</lpage>
          <pub-id pub-id-type="pmid">19546653</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0025">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Armstrong</surname>
              <given-names>R.A.</given-names>
            </name>
          </person-group>
          <article-title>Classic beta-amyloid deposits cluster around large diameter blood vessels rather than capillaries in sporadic Alzheimer's disease</article-title>
          <source>Curr. Neurovasc.</source>
          <volume>3</volume>
          <year>2006</year>
          <fpage>89</fpage>
          <lpage>94</lpage>
        </element-citation>
      </ref>
      <ref id="bb0030">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Attems</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Lintner</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Jellinger</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Amyloid beta peptide 1&#x2013;42 highly correlates with capillary cerebral amyloid angiopathy and Alzheimer disease pathology</article-title>
          <source>Acta Neuropathol.</source>
          <volume>107</volume>
          <year>2004</year>
          <fpage>283</fpage>
          <lpage>291</lpage>
          <pub-id pub-id-type="pmid">14986026</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0035">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Atwood</surname>
              <given-names>C.S.</given-names>
            </name>
            <name>
              <surname>Moir</surname>
              <given-names>R.D.</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Scarpa</surname>
              <given-names>R.C.</given-names>
            </name>
            <name>
              <surname>Bacarra</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Romano</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Hartshorn</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Tanzi</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Bush</surname>
              <given-names>A.I.</given-names>
            </name>
          </person-group>
          <article-title>Dramatic aggregation of Alzheimer Abeta by Cu(II) is induced by conditions representing physiological acidosis</article-title>
          <source>J. Biol. Chem.</source>
          <volume>273</volume>
          <year>1998</year>
          <fpage>12817</fpage>
          <lpage>12826</lpage>
          <pub-id pub-id-type="pmid">9582309</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0040">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Atwood</surname>
              <given-names>C.S.</given-names>
            </name>
            <name>
              <surname>Obrenovich</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Perry</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Martins</surname>
              <given-names>R.N.</given-names>
            </name>
          </person-group>
          <article-title>Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta</article-title>
          <source>Brain Res. Rev.</source>
          <volume>43</volume>
          <year>2003</year>
          <fpage>1</fpage>
          <lpage>16</lpage>
          <pub-id pub-id-type="pmid">14499458</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0045">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barone</surname>
              <given-names>F.C.</given-names>
            </name>
            <name>
              <surname>Rosenbaum</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Crystal</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Vascular cognitive impairment: dementia biology and translational animal models</article-title>
          <source>Curr. Opin. Investig. Drugs</source>
          <volume>10</volume>
          <year>2009</year>
          <fpage>624</fpage>
          <lpage>637</lpage>
        </element-citation>
      </ref>
      <ref id="bb0050">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baydas</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Ozer</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Yasar</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Tuzcu</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Koz</surname>
              <given-names>S.T.</given-names>
            </name>
          </person-group>
          <article-title>Melatonin improves learning and memory performances impaired by hyperhomo-cysteinemia in rats</article-title>
          <source>Brain Res.</source>
          <volume>1046</volume>
          <year>2005</year>
          <fpage>187</fpage>
          <lpage>194</lpage>
          <pub-id pub-id-type="pmid">15882843</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0055">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beal</surname>
              <given-names>M.F.</given-names>
            </name>
          </person-group>
          <article-title>Mitochondria, free radicals, and neurodegeneration</article-title>
          <source>Curr. Opin. Neurobiol.</source>
          <volume>6</volume>
          <year>1996</year>
          <fpage>661</fpage>
          <lpage>666</lpage>
          <pub-id pub-id-type="pmid">8937831</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0060">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boscolo</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Folin</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Nico</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Grandi</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Mangieri</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Longo</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Scienza</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Zampieri</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Conconi</surname>
              <given-names>M.T.</given-names>
            </name>
            <name>
              <surname>Parnigotto</surname>
              <given-names>P.P.</given-names>
            </name>
            <name>
              <surname>Ribatti</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Beta amyloid angiogenic activity in vitro and in vivo</article-title>
          <source>Int. J. Mol. Med.</source>
          <volume>19</volume>
          <year>2007</year>
          <fpage>581</fpage>
          <lpage>587</lpage>
          <pub-id pub-id-type="pmid">17334633</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0065">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brands</surname>
              <given-names>A.M.A.</given-names>
            </name>
            <name>
              <surname>Kessels</surname>
              <given-names>R.P.C.</given-names>
            </name>
            <name>
              <surname>deHaan</surname>
              <given-names>E.H.F.</given-names>
            </name>
            <name>
              <surname>Kappelle</surname>
              <given-names>L.J.</given-names>
            </name>
            <name>
              <surname>Biessels</surname>
              <given-names>G.J.</given-names>
            </name>
          </person-group>
          <article-title>Cerebral dysfunction in type 1 diabetes; effects of insulin, vascular risk factors and blood-glucose levels</article-title>
          <source>Eur. J. Pharmacol.</source>
          <volume>490</volume>
          <year>2004</year>
          <fpage>159</fpage>
          <lpage>168</lpage>
          <pub-id pub-id-type="pmid">15094082</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0070">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Breteler</surname>
              <given-names>M.M.</given-names>
            </name>
          </person-group>
          <article-title>Vascular risk factors for Alzheimer's disease: an epidemiologic perspective</article-title>
          <source>Neurobiol. Aging</source>
          <volume>21</volume>
          <year>2000</year>
          <fpage>153</fpage>
          <lpage>160</lpage>
          <pub-id pub-id-type="pmid">10867200</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0075">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brewer</surname>
              <given-names>G.J.</given-names>
            </name>
          </person-group>
          <article-title>Effects of acidosis on the distribution of processing of the beta-aymloid precursor protein in cultured hippocampal neurons</article-title>
          <source>Mol. Chem. Neuropathol.</source>
          <volume>31</volume>
          <year>1997</year>
          <fpage>171</fpage>
          <lpage>186</lpage>
          <pub-id pub-id-type="pmid">9376023</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0080">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bruno</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Leon</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Fragoso</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Mushynski</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Almazan</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Cuello</surname>
              <given-names>A.C.</given-names>
            </name>
          </person-group>
          <article-title>Amyloid-beta induced nerve growth factor dysmetabolism in Alzheimer disease</article-title>
          <source>J. Neuropathol. Exp. Neurol.</source>
          <volume>68</volume>
          <year>2009</year>
          <fpage>857</fpage>
          <lpage>869</lpage>
          <pub-id pub-id-type="pmid">19606067</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0085">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Butterfield</surname>
              <given-names>D.A.</given-names>
            </name>
            <name>
              <surname>Griffin</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Munch</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Pasinetti</surname>
              <given-names>G.M.</given-names>
            </name>
          </person-group>
          <article-title>Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists</article-title>
          <source>J. Alzheimers Dis.</source>
          <volume>4</volume>
          <year>2002</year>
          <fpage>193</fpage>
          <lpage>201</lpage>
          <pub-id pub-id-type="pmid">12226538</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0090">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Canevari</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Abramov</surname>
              <given-names>A.Y.</given-names>
            </name>
            <name>
              <surname>Duchen</surname>
              <given-names>M.R.</given-names>
            </name>
          </person-group>
          <article-title>Toxicity of amyloid beta peptides: tales of calcium, mitochondria, and oxidative stress</article-title>
          <source>Neurochem. Res.</source>
          <volume>29</volume>
          <year>2004</year>
          <fpage>637</fpage>
          <lpage>650</lpage>
          <pub-id pub-id-type="pmid">15038611</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0095">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carlsson</surname>
              <given-names>C.M.</given-names>
            </name>
          </person-group>
          <article-title>Type 2 diabetes mellitus, dyslipidemia, and Alzheimer&#xB4;s disease</article-title>
          <source>J. Alzheimers Dis.</source>
          <volume>20</volume>
          <year>2010</year>
          <fpage>711</fpage>
          <lpage>722</lpage>
          <pub-id pub-id-type="pmid">20413858</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0100">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Clarke</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>A.D.</given-names>
            </name>
            <name>
              <surname>Jobst</surname>
              <given-names>K.A.</given-names>
            </name>
            <name>
              <surname>Refsum</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Sutton</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Ueland</surname>
              <given-names>P.M.</given-names>
            </name>
          </person-group>
          <article-title>Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease</article-title>
          <source>Arch. Neurol.</source>
          <volume>55</volume>
          <year>1998</year>
          <fpage>1449</fpage>
          <lpage>1455</lpage>
          <pub-id pub-id-type="pmid">9823829</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0105">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Clodfelder-Miller</surname>
              <given-names>B.J.</given-names>
            </name>
            <name>
              <surname>Zmijewska</surname>
              <given-names>A.A.</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>G.V.W.</given-names>
            </name>
            <name>
              <surname>Jope</surname>
              <given-names>R.S.</given-names>
            </name>
          </person-group>
          <article-title>Tau is hyperphosphorylated at multiple sites in mouse brain in vivo after streptozotocin-induced insulin deficiency</article-title>
          <source>Diabetes</source>
          <volume>55</volume>
          <year>2006</year>
          <fpage>3320</fpage>
          <lpage>3325</lpage>
          <pub-id pub-id-type="pmid">17130475</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0110">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cortes-Canteli</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Norris</surname>
              <given-names>E.H.</given-names>
            </name>
            <name>
              <surname>Bronstein</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Ahn</surname>
              <given-names>H.J.</given-names>
            </name>
            <name>
              <surname>Zamolodchikov</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Bhuvanendran</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Fenz</surname>
              <given-names>K.M.</given-names>
            </name>
            <name>
              <surname>Strickland</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer's disease</article-title>
          <source>Neuron</source>
          <volume>66</volume>
          <year>2010</year>
          <fpage>695</fpage>
          <lpage>709</lpage>
          <pub-id pub-id-type="pmid">20547128</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0115">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Counts</surname>
              <given-names>S.E.</given-names>
            </name>
            <name>
              <surname>Nadeem</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Wuu</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Ginsberg</surname>
              <given-names>S.D.</given-names>
            </name>
            <name>
              <surname>Saragovi</surname>
              <given-names>H.U.</given-names>
            </name>
            <name>
              <surname>Mufson</surname>
              <given-names>E.J.</given-names>
            </name>
          </person-group>
          <article-title>Reduction of cortical trkA but not p75NTR protein in early-stage Alzheimer's disease</article-title>
          <source>Ann. Neurol.</source>
          <volume>56</volume>
          <year>2004</year>
          <fpage>520</fpage>
          <lpage>531</lpage>
          <pub-id pub-id-type="pmid">15455399</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0120">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coyle</surname>
              <given-names>J.T.</given-names>
            </name>
            <name>
              <surname>Puttfarcken</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Oxidative stress, glutamate, and neurodegenerative disorders</article-title>
          <source>Science</source>
          <volume>262</volume>
          <year>1993</year>
          <fpage>689</fpage>
          <lpage>695</lpage>
          <pub-id pub-id-type="pmid">7901908</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0125">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cullen</surname>
              <given-names>K.M.</given-names>
            </name>
            <name>
              <surname>Kocsi</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Stone</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Microvascular pathology in the aging human brain: evidence that senile plaques are sites of microhaemorrhages</article-title>
          <source>Neurobiol. Aging</source>
          <volume>27</volume>
          <year>2006</year>
          <fpage>1786</fpage>
          <lpage>1796</lpage>
          <pub-id pub-id-type="pmid">17063559</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0130">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>De la Torre</surname>
              <given-names>J.C.</given-names>
            </name>
          </person-group>
          <article-title>Alzheimer's disease as a vascular disorder</article-title>
          <source>Stroke</source>
          <volume>33</volume>
          <year>2002</year>
          <fpage>1152</fpage>
          <lpage>1162</lpage>
          <pub-id pub-id-type="pmid">11935076</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0135">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de la Torre</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Mussivand</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Can disturbed brain microcirculation cause Alzheimer's Disease?</article-title>
          <source>Neurol. Res.</source>
          <volume>15</volume>
          <year>1993</year>
          <fpage>146</fpage>
          <lpage>153</lpage>
          <pub-id pub-id-type="pmid">8103579</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0140">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>De la Torre</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Stefano</surname>
              <given-names>G.B.</given-names>
            </name>
          </person-group>
          <article-title>Evidence that Alzheimer's disease is a microvascular disorder: the role of constitutive nitric oxide</article-title>
          <source>Brain Res. Brain Res. Rev.</source>
          <volume>34</volume>
          <year>2000</year>
          <fpage>119</fpage>
          <lpage>136</lpage>
          <pub-id pub-id-type="pmid">11113503</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0145">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dede</surname>
              <given-names>D.S.</given-names>
            </name>
            <name>
              <surname>Yavuz</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Yavuz</surname>
              <given-names>B.B.</given-names>
            </name>
            <name>
              <surname>Cankurtaran</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Halil</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Ulger</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Cankurtaran</surname>
              <given-names>E.S.</given-names>
            </name>
            <name>
              <surname>Aytemir</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Kabakci</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Ariogul</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Assessment of endothelial function in Alzheimer's disease: is Alzheimer's disease a vascular disease?</article-title>
          <source>J. Am. Geriatr. Soc.</source>
          <volume>55</volume>
          <year>2007</year>
          <fpage>1613</fpage>
          <lpage>1617</lpage>
          <pub-id pub-id-type="pmid">17711428</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0150">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Del Zoppo</surname>
              <given-names>G.J.</given-names>
            </name>
            <name>
              <surname>Mabuchi</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Cerebral microvessel responses to focal ischemia</article-title>
          <source>J. Cereb. Blood Flow Metab.</source>
          <volume>23</volume>
          <year>2003</year>
          <fpage>879</fpage>
          <lpage>894</lpage>
          <pub-id pub-id-type="pmid">12902832</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0155">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Deschaintre</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Richard</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Leys</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Pasquier</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Treatment of vascular risk factors is associated with slower decline in Alzheimer disease</article-title>
          <source>Neurology</source>
          <volume>73</volume>
          <year>2009</year>
          <fpage>674</fpage>
          <lpage>680</lpage>
          <pub-id pub-id-type="pmid">19720973</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0160">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Engelberg</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Pathogenic factors in vascular dementia and Alzheimer's disease: multiple actions of heparin that probably are beneficial</article-title>
          <source>Dement. Geriatr. Cogn. Dis.</source>
          <volume>18</volume>
          <year>2004</year>
          <fpage>278</fpage>
          <lpage>298</lpage>
        </element-citation>
      </ref>
      <ref id="bb0165">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Erkinjuntti</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Roman</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Gauthier</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Rockwood</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Emerging therapies for vascular dementia and vascular cognitive impairment</article-title>
          <source>Stroke</source>
          <volume>35</volume>
          <year>2004</year>
          <fpage>1010</fpage>
          <lpage>1017</lpage>
          <pub-id pub-id-type="pmid">15001795</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0170">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Erol</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>An integrated and unifying hypothesis for the metabolic basis of sporadic Alzheimers disease</article-title>
          <source>J. Alzheimers Dis.</source>
          <volume>13</volume>
          <year>2008</year>
          <fpage>241</fpage>
          <lpage>253</lpage>
          <pub-id pub-id-type="pmid">18430992</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0175">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fahnestock</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Michalski</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Coughlin</surname>
              <given-names>M.D.</given-names>
            </name>
          </person-group>
          <article-title>The precursor pro-Nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease</article-title>
          <source>Mol. Cell. Neurosci.</source>
          <volume>18</volume>
          <year>2001</year>
          <fpage>210</fpage>
          <lpage>220</lpage>
          <pub-id pub-id-type="pmid">11520181</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0180">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Faraci</surname>
              <given-names>F.M.</given-names>
            </name>
          </person-group>
          <article-title>Hyperhomocysteinemia, A million ways to lose control</article-title>
          <source>Arterioscler. Thromb. Vasc. Biol.</source>
          <volume>23</volume>
          <year>2003</year>
          <fpage>371</fpage>
          <lpage>373</lpage>
          <pub-id pub-id-type="pmid">12639825</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0185">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Farkas</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Luiten</surname>
              <given-names>P.G.M.</given-names>
            </name>
          </person-group>
          <article-title>Cerebral microvascular pathology in aging and Alzheimer's disease</article-title>
          <source>Prog. Neurobiol.</source>
          <volume>64</volume>
          <year>2001</year>
          <fpage>575</fpage>
          <lpage>611</lpage>
          <pub-id pub-id-type="pmid">11311463</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0190">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Flicker</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Martins</surname>
              <given-names>R.N.</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Acres</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Taddei</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Norman</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Jamrozik</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>O.P.</given-names>
            </name>
          </person-group>
          <article-title>Homocysteine, Alzheimer genes and proteins, and measures of cognition and depression in older men</article-title>
          <source>J. Alzheimers Dis.</source>
          <volume>6</volume>
          <year>2004</year>
          <fpage>329</fpage>
          <lpage>336</lpage>
          <pub-id pub-id-type="pmid">15201487</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0195">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Franceschi</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Valensin</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Bonafe</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Paolisso</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Yashin</surname>
              <given-names>A.I.</given-names>
            </name>
            <name>
              <surname>Monti</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>De Benedictis</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>The network and the remodeling theories of aging: historical background and new perspectives</article-title>
          <source>Exp. Gerontol.</source>
          <volume>35</volume>
          <year>2000</year>
          <fpage>879</fpage>
          <lpage>896</lpage>
          <pub-id pub-id-type="pmid">11053678</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0200">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Francis</surname>
              <given-names>P.T.</given-names>
            </name>
            <name>
              <surname>Palmer</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Snape</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Wilcock</surname>
              <given-names>G.K.</given-names>
            </name>
          </person-group>
          <article-title>The cholinergic hypothesis of Alzheimer's disease: a review of progress</article-title>
          <source>J. Neurol. Neurosurg. Psychiatry</source>
          <volume>66</volume>
          <year>1999</year>
          <fpage>137</fpage>
          <lpage>147</lpage>
          <pub-id pub-id-type="pmid">10071091</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0205">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gallucci</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Zanardo</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>De Valentin</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Vianello</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Homocysteine in Alzheimer disease and vascular dementia</article-title>
          <source>Arch. Gerontol. Geriatr. Suppl.</source>
          <volume>9</volume>
          <year>2004</year>
          <fpage>195</fpage>
          <lpage>200</lpage>
          <pub-id pub-id-type="pmid">15207414</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0210">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gearing</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Mirra</surname>
              <given-names>S.S.</given-names>
            </name>
            <name>
              <surname>Hedree</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Sumi</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Hansen</surname>
              <given-names>L.A.</given-names>
            </name>
            <name>
              <surname>Heyman</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>The Consortium to Establish a Registry for Alzheimer&#xB4;'s Disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer&#xB4;'s disease</article-title>
          <source>Neurology</source>
          <volume>45</volume>
          <year>1995</year>
          <fpage>461</fpage>
          <lpage>466</lpage>
          <pub-id pub-id-type="pmid">7898697</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0215">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gonzalez-Scarano</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Baltuch</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Microglia as mediators of inflammatory and degenerative diseases</article-title>
          <source>Annu. Rev. Neurosci.</source>
          <volume>22</volume>
          <year>1999</year>
          <fpage>219</fpage>
          <lpage>240</lpage>
          <pub-id pub-id-type="pmid">10202538</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0220">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grammas</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Ovase</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Cerebrovascular transforming growth factor-beta contributes to inflammation in the Alzheimer's disease brain</article-title>
          <source>Am. J. Pathol.</source>
          <volume>160</volume>
          <year>2002</year>
          <fpage>1583</fpage>
          <lpage>1587</lpage>
          <pub-id pub-id-type="pmid">12000710</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0225">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grammas</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Weigel</surname>
              <given-names>P.H.</given-names>
            </name>
          </person-group>
          <article-title>Microvessels from Alzheimer's disease brains kill neurons in vitro</article-title>
          <source>Am. J. Pathol.</source>
          <volume>154</volume>
          <year>1999</year>
          <fpage>337</fpage>
          <lpage>342</lpage>
          <pub-id pub-id-type="pmid">10027392</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0230">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haglund</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kalaria</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Slade</surname>
              <given-names>J.Y.</given-names>
            </name>
            <name>
              <surname>Englund</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Differential deposition of amyloid beta peptides in cerebral amyloid angiopathy associated with Alzheimer's disease and vascular dementia</article-title>
          <source>Acta Neuropathol.</source>
          <volume>111</volume>
          <year>2006</year>
          <fpage>430</fpage>
          <lpage>435</lpage>
          <pub-id pub-id-type="pmid">16555084</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0235">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hardy</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Cullen</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Amyloid at the blood vessel wall</article-title>
          <source>Nat. Med.</source>
          <volume>12</volume>
          <year>2006</year>
          <fpage>756</fpage>
          <lpage>757</lpage>
          <pub-id pub-id-type="pmid">16829930</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0240">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hardy</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Selkoe</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics</article-title>
          <source>Science</source>
          <volume>298</volume>
          <year>2002</year>
          <fpage>353</fpage>
          <lpage>356</lpage>
          <pub-id pub-id-type="pmid">12376684</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0245">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heinemann</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Zerr</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Demenzen: pPathogenese, neurobiochemische dDiagose sowie reversible Demenz symptome</article-title>
          <source>NeuroForum</source>
          <volume>2/07</volume>
          <year>2007</year>
          <fpage>47</fpage>
          <lpage>54</lpage>
        </element-citation>
      </ref>
      <ref id="bb0250">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hock</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Heese</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>M&#xFC;ller-Spahn</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Riesen</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Nitsch</surname>
              <given-names>R.M.</given-names>
            </name>
            <name>
              <surname>Otten</surname>
              <given-names>U.</given-names>
            </name>
          </person-group>
          <article-title>Increased CSF levels of nerve growth factor in patients with Alzheimer's disease</article-title>
          <source>Neurology</source>
          <volume>54</volume>
          <year>2000</year>
          <fpage>2009</fpage>
          <lpage>2011</lpage>
          <pub-id pub-id-type="pmid">10822447</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0255">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Honig</surname>
              <given-names>L.S.</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>M.X.</given-names>
            </name>
            <name>
              <surname>Albert</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Costa</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Luchsinger</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Manly</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Stern</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Mayeux</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Stroke and the risk of Alzheimer disease</article-title>
          <source>Arch. Neurol.</source>
          <volume>60</volume>
          <year>2003</year>
          <fpage>1707</fpage>
          <lpage>1712</lpage>
          <pub-id pub-id-type="pmid">14676044</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0260">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Humpel</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Marksteiner</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Cerebrovascular damage as a cause for Alzheimer's disease?</article-title>
          <source>Curr. Neurovasc. Res.</source>
          <volume>2</volume>
          <year>2005</year>
          <fpage>341</fpage>
          <lpage>347</lpage>
          <pub-id pub-id-type="pmid">16181125</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0265">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Humpel</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Weis</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Nerve growth factor and cholinergic CNS neurons studied in organotypic brain slices: implications in Alzheimer's disease</article-title>
          <source>J. Neural Transm.</source>
          <volume>62</volume>
          <year>2002</year>
          <fpage>253</fpage>
          <lpage>263</lpage>
        </element-citation>
      </ref>
      <ref id="bb0270">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iadecola</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Neurovascular regulation in the normal brain and in Alzheimer's disease</article-title>
          <source>Nat. Rev. Neurosci.</source>
          <volume>5</volume>
          <year>2004</year>
          <fpage>347</fpage>
          <lpage>360</lpage>
          <pub-id pub-id-type="pmid">15100718</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0275">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iqbal</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Alonso</surname>
              <given-names>Adel C.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Chohan</surname>
              <given-names>M.O.</given-names>
            </name>
            <name>
              <surname>El-Akkad</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Gong</surname>
              <given-names>C.X.</given-names>
            </name>
            <name>
              <surname>Khatoon</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Rahman</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Tanimukai</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Grundke-Iqbal</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>Tau pathology in Alzheimer disease and other tauopathies</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>1739</volume>
          <year>2005</year>
          <fpage>198</fpage>
          <lpage>210</lpage>
          <pub-id pub-id-type="pmid">15615638</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0280">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ishii</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Sasaki</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Matsui</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sakamoto</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Yamaji</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Hayashi</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Mori</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Kitagaki</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Hirono</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Mori</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>A diagnostic method for suspected Alzheimer's disease using H(2)15O positron emission tomography perfusion Z score</article-title>
          <source>Neuroradiology</source>
          <volume>42</volume>
          <year>2000</year>
          <fpage>787</fpage>
          <lpage>794</lpage>
          <pub-id pub-id-type="pmid">11151682</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0285">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kalaria</surname>
              <given-names>R.N.</given-names>
            </name>
          </person-group>
          <article-title>The role of cerebral ischemia in Alzheimer's disease</article-title>
          <source>Neurobiol. Aging</source>
          <volume>21</volume>
          <year>2000</year>
          <fpage>321</fpage>
          <lpage>330</lpage>
          <pub-id pub-id-type="pmid">10867217</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0290">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kalaria</surname>
              <given-names>R.N.</given-names>
            </name>
          </person-group>
          <article-title>Neurodegenerative disease: diabetes, microvascular pathology and Alzheimer&#xB4;s disease</article-title>
          <source>Nat. Rev. Neurol.</source>
          <volume>5</volume>
          <year>2009</year>
          <fpage>305</fpage>
          <lpage>306</lpage>
          <pub-id pub-id-type="pmid">19498432</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0295">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>J.-M.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>H.J.</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Hyperhomocysteinemia due to short-term folate deprivation is related to electron microscopic changes in the rat brain</article-title>
          <source>J. Nutr.</source>
          <volume>132</volume>
          <year>2002</year>
          <fpage>3418</fpage>
          <lpage>3421</lpage>
          <pub-id pub-id-type="pmid">12421861</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0300">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kovac</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Zilkova</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Deli</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Zilka</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Novak</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Human truncated tau is using a different mechanism from amyloid-beta to damage the blood-brain barrier</article-title>
          <source>J. Alzheimers Dis.</source>
          <volume>18</volume>
          <issue>4</issue>
          <year>2009</year>
          <fpage>897</fpage>
          <lpage>906</lpage>
          <pub-id pub-id-type="pmid">19749439</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0305">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kovari</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Gold</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Herrmann</surname>
              <given-names>F.R.</given-names>
            </name>
            <name>
              <surname>Canuto</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Hof</surname>
              <given-names>P.R.</given-names>
            </name>
            <name>
              <surname>Bouras</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Giannakopoulos</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Cortical microinfarcts and demyelination affect cognition in cases at high risk for dementia</article-title>
          <source>Neurology</source>
          <volume>68</volume>
          <year>2007</year>
          <fpage>927</fpage>
          <lpage>931</lpage>
          <pub-id pub-id-type="pmid">17372128</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0310">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kudo</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Imaizumu</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Tanimukai</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Katayama</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Kashiwagi</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Jinno</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Tohyama</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Takeda</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Are cerebrovascular factors invlolved in Alzheimer's disease AD?</article-title>
          <source>Neurobiol. Aging</source>
          <volume>21</volume>
          <year>2000</year>
          <fpage>215</fpage>
          <lpage>224</lpage>
          <pub-id pub-id-type="pmid">10867206</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0315">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Langa</surname>
              <given-names>K.M.</given-names>
            </name>
            <name>
              <surname>Foster</surname>
              <given-names>N.L.</given-names>
            </name>
            <name>
              <surname>Larson</surname>
              <given-names>E.B.</given-names>
            </name>
          </person-group>
          <article-title>Mixed dementia, emerging concepts and therapeutic implications</article-title>
          <source>Jama</source>
          <volume>292</volume>
          <year>2004</year>
          <fpage>2901</fpage>
          <lpage>2908</lpage>
          <pub-id pub-id-type="pmid">15598922</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0320">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>H.-J.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>J.-M.</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Effects of dietary folic acid supplementation on cerebrovascular endothelial dysfunction in rats with induced hyperhomocysteinemia</article-title>
          <source>Brain Res.</source>
          <volume>996</volume>
          <year>2004</year>
          <fpage>139</fpage>
          <lpage>147</lpage>
          <pub-id pub-id-type="pmid">14697491</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0325">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Letenneur</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Risk of dementia and alcohol and wine consumption: a review of recent results</article-title>
          <source>Biol. Res.</source>
          <volume>37</volume>
          <year>2004</year>
          <fpage>189</fpage>
          <lpage>193</lpage>
          <pub-id pub-id-type="pmid">15455646</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0330">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Levi-Montalcini</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>The nerve growth factor, thirty-five years later</article-title>
          <source>Biosci. Rep.</source>
          <volume>7</volume>
          <year>1987</year>
          <fpage>681</fpage>
          <lpage>699</lpage>
          <pub-id pub-id-type="pmid">3322422</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0335">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Siesjo</surname>
              <given-names>B.K.</given-names>
            </name>
          </person-group>
          <article-title>Role of hyperglycaemia-related acidosis in ischemic brain damage</article-title>
          <source>Acta Physiol. Scand.</source>
          <volume>161</volume>
          <year>1997</year>
          <fpage>567</fpage>
          <lpage>580</lpage>
          <pub-id pub-id-type="pmid">9429666</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0340">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Linden</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Skoog</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Fagerberg</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Steen</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Blomstrand</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Cognitive impairment and dementia 20&#xA0;months after stroke</article-title>
          <source>Neuroepidemiology</source>
          <volume>23</volume>
          <year>2004</year>
          <fpage>45</fpage>
          <lpage>52</lpage>
          <pub-id pub-id-type="pmid">14739567</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0345">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lipton</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>W.-K.</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>Y.-B.</given-names>
            </name>
            <name>
              <surname>Kumar</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>D'Emilia</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Rayudu</surname>
              <given-names>P.V.</given-names>
            </name>
            <name>
              <surname>Arnelle</surname>
              <given-names>D.R.</given-names>
            </name>
            <name>
              <surname>Stamler</surname>
              <given-names>J.S.</given-names>
            </name>
          </person-group>
          <article-title>Neurotoxicity associated with dual actions of homocysteine at the N-methyl-<sc>d</sc>D-aspartate receptor</article-title>
          <source>Proc. Natl Acad. Sci. USA</source>
          <volume>94</volume>
          <year>1997</year>
          <fpage>5923</fpage>
          <lpage>5928</lpage>
          <pub-id pub-id-type="pmid">9159176</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0350">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Luchsinger</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>M.X.</given-names>
            </name>
            <name>
              <surname>Shea</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Mayeux</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Plasma homocysteine levels and risk of Alzheimer disease</article-title>
          <source>Neurology</source>
          <volume>62</volume>
          <year>2004</year>
          <fpage>1972</fpage>
          <lpage>1976</lpage>
          <pub-id pub-id-type="pmid">15184599</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0355">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mandelkow</surname>
              <given-names>E.M.</given-names>
            </name>
            <name>
              <surname>Mandelkow</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Tau in Alzheimer's disease</article-title>
          <source>Trends Cell Biol.</source>
          <volume>8</volume>
          <year>1998</year>
          <fpage>425</fpage>
          <lpage>427</lpage>
          <pub-id pub-id-type="pmid">9854307</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0360">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marchesi</surname>
              <given-names>V.T.</given-names>
            </name>
          </person-group>
          <article-title>An alternative interpretation of the amyloid Abeta hypothesis with regard to the pathogenesis of Alzheimer's disease</article-title>
          <source>Pnas</source>
          <volume>102</volume>
          <year>2005</year>
          <fpage>9093</fpage>
          <lpage>9098</lpage>
          <pub-id pub-id-type="pmid">15967987</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0365">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marcus</surname>
              <given-names>D.L.</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Rodriguez</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Simberkoff</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Tsai</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Strafaci</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Freedman</surname>
              <given-names>M.L.</given-names>
            </name>
          </person-group>
          <article-title>Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease</article-title>
          <source>Exp. Neurol.</source>
          <volume>150</volume>
          <year>1998</year>
          <fpage>40</fpage>
          <lpage>44</lpage>
          <pub-id pub-id-type="pmid">9514828</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0370">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Markesbery</surname>
              <given-names>W.R.</given-names>
            </name>
            <name>
              <surname>Carney</surname>
              <given-names>J.M.</given-names>
            </name>
          </person-group>
          <article-title>Oxidative alterations in Alzheimer's disease</article-title>
          <source>Brain Pathol.</source>
          <volume>9</volume>
          <year>1999</year>
          <fpage>133</fpage>
          <lpage>146</lpage>
          <pub-id pub-id-type="pmid">9989456</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0375">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marksteiner</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Humpel</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Beta-amyloid expression, release and extracellular deposition in aged rat brain slices</article-title>
          <source>Mol. Psychiatry</source>
          <volume>13</volume>
          <year>2008</year>
          <fpage>939</fpage>
          <lpage>952</lpage>
          <pub-id pub-id-type="pmid">17712316</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0380">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matsunaga</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Fujii</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Awasthi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Yokotani</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Takakura</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Yamada</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Eight residue amyloid beta peptides inhibit the aggregation and enzymatic activity of amyloid-beta42</article-title>
          <source>Regul. Pept.</source>
          <volume>120</volume>
          <year>1994</year>
          <fpage>227</fpage>
          <lpage>236</lpage>
          <pub-id pub-id-type="pmid">15177941</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0385">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McIlroy</surname>
              <given-names>S.P.</given-names>
            </name>
            <name>
              <surname>Dynan</surname>
              <given-names>K.B.</given-names>
            </name>
            <name>
              <surname>Lawson</surname>
              <given-names>J.T.</given-names>
            </name>
            <name>
              <surname>Patterson</surname>
              <given-names>C.C.</given-names>
            </name>
            <name>
              <surname>Passmore</surname>
              <given-names>A.P.</given-names>
            </name>
          </person-group>
          <article-title>Moderately elevated plasma homocysteine, methylenetetra-hydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland</article-title>
          <source>Stroke</source>
          <volume>33</volume>
          <year>2002</year>
          <fpage>2351</fpage>
          <lpage>2356</lpage>
          <pub-id pub-id-type="pmid">12364720</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0390">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moore</surname>
              <given-names>A.H.</given-names>
            </name>
            <name>
              <surname>O'Banion</surname>
              <given-names>M.K.</given-names>
            </name>
          </person-group>
          <article-title>Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease</article-title>
          <source>Adv. Drug Deliv. Rev.</source>
          <volume>54</volume>
          <year>2002</year>
          <fpage>1627</fpage>
          <lpage>1656</lpage>
          <pub-id pub-id-type="pmid">12453679</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0400">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mosconi</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Berti</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Glodzik</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Pupi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>De Santi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>de Leon</surname>
              <given-names>M.J.</given-names>
            </name>
          </person-group>
          <article-title>Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging</article-title>
          <source>J. Alzheimers Dis.</source>
          <volume>20</volume>
          <year>2010</year>
          <fpage>843</fpage>
          <lpage>854</lpage>
          <pub-id pub-id-type="pmid">20182025</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0405">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moser</surname>
              <given-names>K.V.</given-names>
            </name>
            <name>
              <surname>Humpel</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Blood-derived serum albumin contributes to neurodegeneration via astroglial stress fiber formation</article-title>
          <source>Pharmacology</source>
          <volume>80</volume>
          <issue>4</issue>
          <year>2007</year>
          <fpage>286</fpage>
          <lpage>292</lpage>
          <pub-id pub-id-type="pmid">17671402</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0410">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moser</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Reindl</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Blasig</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Humpel</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Brain capillary endothelial cells proliferate in response to NGF, express NGF receptors and secrete NGF after inflammation</article-title>
          <source>Brain Res.</source>
          <volume>1017</volume>
          <year>2004</year>
          <fpage>53</fpage>
          <lpage>60</lpage>
          <pub-id pub-id-type="pmid">15261099</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0415">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mufson</surname>
              <given-names>E.J.</given-names>
            </name>
            <name>
              <surname>Kroin</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Sendera</surname>
              <given-names>T.J.</given-names>
            </name>
            <name>
              <surname>Sobreviela</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases</article-title>
          <source>Prog. Neurobiol.</source>
          <volume>57</volume>
          <year>1999</year>
          <fpage>451</fpage>
          <lpage>484</lpage>
          <pub-id pub-id-type="pmid">10080385</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0420">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mufson</surname>
              <given-names>E.J.</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>S.Y.</given-names>
            </name>
            <name>
              <surname>Dills</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Cochran</surname>
              <given-names>E.J.</given-names>
            </name>
            <name>
              <surname>Leurgans</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Wuu</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Bennett</surname>
              <given-names>D.A.</given-names>
            </name>
            <name>
              <surname>Jaffar</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Gilmor</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Levey</surname>
              <given-names>A.I.</given-names>
            </name>
            <name>
              <surname>Kordower</surname>
              <given-names>J.H.</given-names>
            </name>
          </person-group>
          <article-title>Loss of basal forebrain p75NTR immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease</article-title>
          <source>J. Comp. Neurol.</source>
          <volume>443</volume>
          <year>2002</year>
          <fpage>136</fpage>
          <lpage>153</lpage>
          <pub-id pub-id-type="pmid">11793352</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0425">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nunomura</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Perry</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Pappolla</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Wade</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Hirai</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Chiba</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>M.A.</given-names>
            </name>
          </person-group>
          <article-title>RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease</article-title>
          <source>J. Neurosci.</source>
          <volume>19</volume>
          <year>1999</year>
          <fpage>1959</fpage>
          <lpage>1964</lpage>
          <pub-id pub-id-type="pmid">10066249</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0430">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Olanow</surname>
              <given-names>C.W.</given-names>
            </name>
          </person-group>
          <article-title>A radical hypothesis for neurodegeneration</article-title>
          <source>Trends Neurosci.</source>
          <volume>16</volume>
          <year>1993</year>
          <fpage>439</fpage>
          <lpage>444</lpage>
          <pub-id pub-id-type="pmid">7507613</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0435">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ott</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Stolk</surname>
              <given-names>R.P.</given-names>
            </name>
            <name>
              <surname>van Harskamp</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Pols</surname>
              <given-names>H.A.</given-names>
            </name>
            <name>
              <surname>Hofman</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Breteler</surname>
              <given-names>M.M.</given-names>
            </name>
          </person-group>
          <article-title>Diabetes mellitus and the risk of dementia: the rotterdam study</article-title>
          <source>Neurology</source>
          <volume>53</volume>
          <year>1999</year>
          <fpage>1937</fpage>
          <lpage>1942</lpage>
          <pub-id pub-id-type="pmid">10599761</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0440">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Perry</surname>
              <given-names>V.H.</given-names>
            </name>
            <name>
              <surname>Bell</surname>
              <given-names>M.D.</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>H.C.</given-names>
            </name>
            <name>
              <surname>Matyszak</surname>
              <given-names>M.K.</given-names>
            </name>
          </person-group>
          <article-title>Inflammation in the nervous system</article-title>
          <source>Curr. Opin. Neurobiol.</source>
          <volume>5</volume>
          <year>1995</year>
          <fpage>636</fpage>
          <lpage>641</lpage>
          <pub-id pub-id-type="pmid">8580715</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0445">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pinder</surname>
              <given-names>R.M.</given-names>
            </name>
            <name>
              <surname>Sandler</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Alcohol, wine and mental health: focus on dementia and stroke</article-title>
          <source>J. Psychopharmacol.</source>
          <volume>18</volume>
          <year>2004</year>
          <fpage>449</fpage>
          <lpage>456</lpage>
          <pub-id pub-id-type="pmid">15582912</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0450">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pirchl</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Marksteiner</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Humpel</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Effects of acidosis on brain capillary endothelial cells and cholinergic neurons: relevance for vascular dementia and Alzheimer's disease</article-title>
          <source>Neurol. Res.</source>
          <volume>28</volume>
          <year>2006</year>
          <fpage>657</fpage>
          <lpage>664</lpage>
          <pub-id pub-id-type="pmid">16945219</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0455">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Raffai</surname>
              <given-names>R.L.</given-names>
            </name>
            <name>
              <surname>Weisgraber</surname>
              <given-names>K.H.</given-names>
            </name>
          </person-group>
          <article-title>Cholesterol, from heart attacks to Alzheimer's diseaseAD</article-title>
          <source>J. Lipid Res.</source>
          <volume>44</volume>
          <year>2003</year>
          <fpage>1423</fpage>
          <lpage>1430</lpage>
          <pub-id pub-id-type="pmid">12837845</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0460">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rasquin</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Verhey</surname>
              <given-names>F.R.</given-names>
            </name>
            <name>
              <surname>van Oostenbrugge</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Lousberg</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Lodder</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Demographic and CT scan features related to cognitive impairment in the first year after stroke</article-title>
          <source>J. Neurol. Neurosurg. Psychiatry</source>
          <volume>75</volume>
          <year>2004</year>
          <fpage>1562</fpage>
          <lpage>1567</lpage>
          <pub-id pub-id-type="pmid">15489388</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0465">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ravaglia</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Forti</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Maioli</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Martelli</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Servadei</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Brunetti</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Porcellini</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Licastro</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Homocysteine and folate as risk factors for dementia and Alzheimer disease</article-title>
          <source>Am. J. Clin. Nutr.</source>
          <volume>82</volume>
          <year>2005</year>
          <fpage>636</fpage>
          <lpage>643</lpage>
          <pub-id pub-id-type="pmid">16155278</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0470">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Refolo</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Pappolla</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Malester</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>LaFrancois</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Bryant-Thomas</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Tint</surname>
              <given-names>G.S.</given-names>
            </name>
            <name>
              <surname>Sambamurti</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Duff</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model</article-title>
          <source>Neurobiol. Dis.</source>
          <volume>7</volume>
          <year>2000</year>
          <fpage>321</fpage>
          <lpage>331</lpage>
          <pub-id pub-id-type="pmid">10964604</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0475">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rehncrona</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Brain acidosis</article-title>
          <source>Ann. Emerg. Med.</source>
          <volume>14</volume>
          <year>1985</year>
          <fpage>770</fpage>
          <lpage>776</lpage>
          <pub-id pub-id-type="pmid">3927794</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0480">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Robakis</surname>
              <given-names>N.K.</given-names>
            </name>
          </person-group>
          <article-title>Are Abeta and its derivatives causative agents or innocent bystanders in AD?</article-title>
          <source>Neurodegener. Dis.</source>
          <volume>7</volume>
          <year>2010</year>
          <fpage>32</fpage>
          <lpage>37</lpage>
          <pub-id pub-id-type="pmid">20160455</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0485">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rocchi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Orsucci</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Tognoni</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Ceravolo</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Siciliano</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>The role of vascular factors in late-onset sporadic Alzheimer&#xB4;s disease. Genetic and molecular aspects</article-title>
          <source>Curr. Alzheimer Res.</source>
          <volume>6</volume>
          <year>2009</year>
          <fpage>224</fpage>
          <lpage>237</lpage>
          <pub-id pub-id-type="pmid">19519304</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0490">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roman</surname>
              <given-names>G.C.</given-names>
            </name>
          </person-group>
          <article-title>Facts, myths, and controversies in vascular dementia</article-title>
          <source>J. Neurol. Sci.</source>
          <volume>226</volume>
          <year>2004</year>
          <fpage>49</fpage>
          <lpage>52</lpage>
          <pub-id pub-id-type="pmid">15537519</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0495">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roth</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>The natural history of mental disorder in old age</article-title>
          <source>J. Ment. Sci.</source>
          <volume>101</volume>
          <year>1955</year>
          <fpage>281</fpage>
          <lpage>301</lpage>
          <pub-id pub-id-type="pmid">13243044</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0500">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sadowski</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Pankiewicz</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Scholtzova</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Y.-S.</given-names>
            </name>
            <name>
              <surname>Quartermain</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Duff</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Wisniewski</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Links between the pathology of Alzheimer's disease and vascular dementia</article-title>
          <source>Neurochem. Res.</source>
          <volume>29</volume>
          <year>2004</year>
          <fpage>1257</fpage>
          <lpage>1266</lpage>
          <pub-id pub-id-type="pmid">15176482</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0505">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Saez</surname>
              <given-names>T.E.</given-names>
            </name>
            <name>
              <surname>Pehar</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Vargas</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Barbeito</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Maccioni</surname>
              <given-names>R.B.</given-names>
            </name>
          </person-group>
          <article-title>Astrocytic nitric oxide triggers tau hyperphosphorylation in hippocampal neurons</article-title>
          <source>In Vivo</source>
          <volume>18</volume>
          <issue>3</issue>
          <year>2004</year>
          <fpage>275</fpage>
          <lpage>280</lpage>
          <comment>May-Jun</comment>
          <pub-id pub-id-type="pmid">15341183</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0510">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schroeder</surname>
              <given-names>B.E.</given-names>
            </name>
            <name>
              <surname>Koo</surname>
              <given-names>E.H.</given-names>
            </name>
          </person-group>
          <article-title>To think or not to think: synaptic activity and Abeta release</article-title>
          <source>Neuron</source>
          <volume>48</volume>
          <year>2005</year>
          <fpage>873</fpage>
          <lpage>879</lpage>
          <pub-id pub-id-type="pmid">16364890</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0515">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schubert</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Ogata</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Marchini</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Ferroni</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Glia-related pathomechanisms in Alzheimer's disease: a therapeutic target?</article-title>
          <source>Mech. Ageing Dev.</source>
          <volume>123</volume>
          <year>2001</year>
          <fpage>47</fpage>
          <lpage>57</lpage>
          <pub-id pub-id-type="pmid">11640951</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0520">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seiger</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Nordberg</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Von Holst</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>B&#xE4;ckman</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Ebendal</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Alafuzoff</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Amberla</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Hartvig</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Herlitz</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Lilja</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Lundqvist</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Langstr&#xF6;m</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Meyerson</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Persson</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Viitanen</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Winblad</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Olson</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Intracranial infusion of purified nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment strategy</article-title>
          <source>Behav. Brain Res.</source>
          <volume>57</volume>
          <year>1993</year>
          <fpage>255</fpage>
          <lpage>261</lpage>
          <pub-id pub-id-type="pmid">8117429</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0525">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Selkoe</surname>
              <given-names>D.J.</given-names>
            </name>
          </person-group>
          <article-title>The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease</article-title>
          <source>Trends Cell Biol.</source>
          <volume>8</volume>
          <year>1998</year>
          <fpage>447</fpage>
          <lpage>453</lpage>
          <pub-id pub-id-type="pmid">9854312</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0530">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Selkoe</surname>
              <given-names>D.J.</given-names>
            </name>
          </person-group>
          <article-title>Alzheimer's disease is a synaptic failure</article-title>
          <source>Science</source>
          <volume>298</volume>
          <year>2002</year>
          <fpage>789</fpage>
          <lpage>791</lpage>
          <pub-id pub-id-type="pmid">12399581</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0535">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seshadri</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Beiser</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Selhub</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Jaques</surname>
              <given-names>P.F.</given-names>
            </name>
            <name>
              <surname>Rosenberg</surname>
              <given-names>I.H.</given-names>
            </name>
            <name>
              <surname>D&#xB4;Agostino</surname>
              <given-names>R.B.</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>P.W.F.</given-names>
            </name>
            <name>
              <surname>Wolf</surname>
              <given-names>P.A.</given-names>
            </name>
          </person-group>
          <article-title>Plasma homocysteine as a risk factor for dementia and Alzheimer's disease</article-title>
          <source>New Engl. J. Med.</source>
          <volume>346</volume>
          <year>2002</year>
          <fpage>476</fpage>
          <lpage>483</lpage>
          <pub-id pub-id-type="pmid">11844848</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0540">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sharp</surname>
              <given-names>C.D.</given-names>
            </name>
            <name>
              <surname>Hines</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Houghton</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Warren</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>T.H.</given-names>
            </name>
            <name>
              <surname>Jawahar</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Nanda</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Elrod</surname>
              <given-names>J.W.</given-names>
            </name>
            <name>
              <surname>Long</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Chi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Minagar</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Alexander</surname>
              <given-names>J.S.</given-names>
            </name>
          </person-group>
          <article-title>Glutamate causes a loss in human cerebral endothelial barrier integrity through activation of NMDA receptor</article-title>
          <source>Am. J. Physiol. Heart Cir. Physiol.</source>
          <volume>285</volume>
          <year>2003</year>
          <fpage>H2592</fpage>
          <lpage>H2598</lpage>
        </element-citation>
      </ref>
      <ref id="bb0545">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shie</surname>
              <given-names>F.-S.</given-names>
            </name>
            <name>
              <surname>Jin</surname>
              <given-names>L.-W.</given-names>
            </name>
            <name>
              <surname>Cook</surname>
              <given-names>D.G.</given-names>
            </name>
            <name>
              <surname>Leverenz</surname>
              <given-names>J.B.</given-names>
            </name>
            <name>
              <surname>LeBouef</surname>
              <given-names>R.C.</given-names>
            </name>
          </person-group>
          <article-title>Diet-induced hypercholesterolemia enhances brain Abeta accumulation in transgenic mice</article-title>
          <source>NeuroReport</source>
          <volume>13</volume>
          <year>2002</year>
          <fpage>455</fpage>
          <lpage>459</lpage>
          <pub-id pub-id-type="pmid">11930160</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0550">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Siesjo</surname>
              <given-names>B.K.</given-names>
            </name>
          </person-group>
          <article-title>Acidosis and ischemic brain damage</article-title>
          <source>Neurochem. Pathol.</source>
          <volume>9</volume>
          <year>1988</year>
          <fpage>31</fpage>
          <lpage>88</lpage>
          <pub-id pub-id-type="pmid">3073332</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0555">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Siesjo</surname>
              <given-names>B.K.</given-names>
            </name>
          </person-group>
          <article-title>Pathophysiology and treatment of focal cerebral ischemia. Part I: Pathophysiology</article-title>
          <source>J. Neurosurg.</source>
          <volume>77</volume>
          <year>1992</year>
          <fpage>169</fpage>
          <lpage>184</lpage>
          <pub-id pub-id-type="pmid">1625004</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0560">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Skurk</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Walsh</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Death receptor induced apoptosis, a new mechanism of homocysteine-mediated endothelial cell cytotoxicity</article-title>
          <source>Hypertension</source>
          <volume>43</volume>
          <year>2004</year>
          <fpage>1168</fpage>
          <lpage>1170</lpage>
          <pub-id pub-id-type="pmid">15096473</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0565">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smith</surname>
              <given-names>E.E.</given-names>
            </name>
            <name>
              <surname>Greenberg</surname>
              <given-names>S.M.</given-names>
            </name>
          </person-group>
          <article-title>Beta-amyloid, blood vessels, and brain function</article-title>
          <source>Stroke</source>
          <volume>40</volume>
          <year>2009</year>
          <fpage>2601</fpage>
          <lpage>2606</lpage>
          <pub-id pub-id-type="pmid">19443808</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0570">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smith</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Drew</surname>
              <given-names>K.L.</given-names>
            </name>
            <name>
              <surname>Nunomura</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Takeda</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Hirai</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Atwood</surname>
              <given-names>C.S.</given-names>
            </name>
            <name>
              <surname>Raina</surname>
              <given-names>A.K.</given-names>
            </name>
            <name>
              <surname>Rottkamp</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Sayre</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Friedland</surname>
              <given-names>R.P.</given-names>
            </name>
            <name>
              <surname>Perry</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Amyloid-beta, tau alterations and mitochondrial dysfunction in Alzheimer disease: the chickens or the eggs?</article-title>
          <source>Neurochem. Int.</source>
          <volume>40</volume>
          <year>2002</year>
          <fpage>527</fpage>
          <lpage>531</lpage>
          <pub-id pub-id-type="pmid">11850109</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0575">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Soffer</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Cerebral amyloid angiopathy &#x2014; a disease or age-related condition</article-title>
          <source>Isr. Med. Assoc. J.</source>
          <volume>8</volume>
          <year>2006</year>
          <fpage>803</fpage>
          <lpage>806</lpage>
          <pub-id pub-id-type="pmid">17180835</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0580">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Solfrizzi</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Panza</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Colacicco</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>D'Introno</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Capurso</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Torres</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Grigoletto</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Maggi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Del Parigi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Reiman</surname>
              <given-names>E.M.</given-names>
            </name>
            <name>
              <surname>Caselli</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Scafato</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Farchi</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Capurso</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Vascular risk factors, incidence of MCI, and rates of progression to dementia</article-title>
          <source>Neurology</source>
          <volume>63</volume>
          <year>2004</year>
          <fpage>1882</fpage>
          <lpage>1891</lpage>
          <pub-id pub-id-type="pmid">15557506</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0585">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sparks</surname>
              <given-names>D.L.</given-names>
            </name>
            <name>
              <surname>Scheff</surname>
              <given-names>S.W.</given-names>
            </name>
            <name>
              <surname>Hunsaker</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Landers</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Gross</surname>
              <given-names>D.R.</given-names>
            </name>
          </person-group>
          <article-title>Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol</article-title>
          <source>Exp. Neurol.</source>
          <volume>126</volume>
          <year>1994</year>
          <fpage>88</fpage>
          <lpage>94</lpage>
          <pub-id pub-id-type="pmid">8157129</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0590">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Spillantini</surname>
              <given-names>M.G.</given-names>
            </name>
            <name>
              <surname>Goedert</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Tau protein pathology in neurodegenerative diseases</article-title>
          <source>Trends Neurosci.</source>
          <volume>21</volume>
          <year>1998</year>
          <fpage>428</fpage>
          <lpage>433</lpage>
          <pub-id pub-id-type="pmid">9786340</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0595">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takechi</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Galloway</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Pallebage-Gamarallage</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Lam</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Mamo</surname>
              <given-names>J.C.</given-names>
            </name>
          </person-group>
          <article-title>Dietary fats, cerebrovasculature integrity and Alzheimers disease risk</article-title>
          <source>Prog. Lipid Res.</source>
          <volume>49</volume>
          <year>2010</year>
          <fpage>159</fpage>
          <lpage>170</lpage>
          <pub-id pub-id-type="pmid">19896503</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0600">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tanzi</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Bertram</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Twenty years of the Alzheimer's disease AD amyloid hypothesis, a genetic perspective</article-title>
          <source>Cell</source>
          <volume>120</volume>
          <year>2005</year>
          <fpage>545</fpage>
          <lpage>555</lpage>
          <pub-id pub-id-type="pmid">15734686</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0605">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tanzi</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Moir</surname>
              <given-names>R.D.</given-names>
            </name>
            <name>
              <surname>Wagner</surname>
              <given-names>S.L.</given-names>
            </name>
          </person-group>
          <article-title>Clearance of Alzheimer&#xB4;s Abeta peptide, the many roads to perdition</article-title>
          <source>Neuron</source>
          <volume>43</volume>
          <year>2004</year>
          <fpage>505</fpage>
          <lpage>608</lpage>
        </element-citation>
      </ref>
      <ref id="bb0610">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thal</surname>
              <given-names>D.R.</given-names>
            </name>
            <name>
              <surname>Ghebremedhin</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Orantes</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Wiestler</surname>
              <given-names>O.D.</given-names>
            </name>
          </person-group>
          <article-title>Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline</article-title>
          <source>J. Neuropathol. Exp. Neurol.</source>
          <volume>62</volume>
          <year>2003</year>
          <fpage>1287</fpage>
          <lpage>1301</lpage>
          <pub-id pub-id-type="pmid">14692704</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0615">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thoenen</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Barde</surname>
              <given-names>Y.-A.</given-names>
            </name>
          </person-group>
          <article-title>Physiology of nerve growth factor</article-title>
          <source>Physiol. Rev.</source>
          <volume>60</volume>
          <year>1980</year>
          <fpage>1284</fpage>
          <lpage>1335</lpage>
          <pub-id pub-id-type="pmid">6159658</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0620">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Troen</surname>
              <given-names>A.M.</given-names>
            </name>
          </person-group>
          <article-title>The central nervous system in animal models of hyperhomocysteinemia</article-title>
          <source>Prog. Neuro-Psychopharmacol. Biol. Psychiatry</source>
          <volume>29</volume>
          <year>2005</year>
          <fpage>1140</fpage>
          <lpage>1151</lpage>
        </element-citation>
      </ref>
      <ref id="bb0625">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tyas</surname>
              <given-names>S.L.</given-names>
            </name>
          </person-group>
          <article-title>Alcohol use and the risk of developing Alzheimers disease</article-title>
          <source>Alcohol Res. Health</source>
          <volume>25</volume>
          <year>2001</year>
          <fpage>299</fpage>
          <lpage>306</lpage>
          <pub-id pub-id-type="pmid">11910708</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0630">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Varma</surname>
              <given-names>A.R.</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Lloyd</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>Carson</surname>
              <given-names>K.J.</given-names>
            </name>
            <name>
              <surname>Snowden</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Testa</surname>
              <given-names>H.J.</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Neary</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Diagnostic patterns of regional atrophy on MRI and regional cerebral blood flow change on SPECT in young onset patients with Alzheimer's disease, frontotemporal dementia and vascular dementia</article-title>
          <source>Acta Neurol. Scand.</source>
          <volume>105</volume>
          <year>2002</year>
          <fpage>261</fpage>
          <lpage>269</lpage>
          <pub-id pub-id-type="pmid">11939938</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0635">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vaucher</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Hamel</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Cholinergic basal forebrain neurons project to cortical microvessels in the rat: electron microscopic study with anterograde transported <italic>Phaesolus vulgaris</italic> leucoagglutinin and choline acetyltransferase immunocytochemistry</article-title>
          <source>J. Neurosci.</source>
          <volume>15</volume>
          <year>1995</year>
          <fpage>7427</fpage>
          <lpage>7441</lpage>
          <pub-id pub-id-type="pmid">7472495</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0640">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Walsh</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Klyubin</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Fadeeva</surname>
              <given-names>J.V.</given-names>
            </name>
            <name>
              <surname>Rowan</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Selkoe</surname>
              <given-names>D.J.</given-names>
            </name>
          </person-group>
          <article-title>Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition</article-title>
          <source>Biochem. Soc. Trans.</source>
          <volume>30</volume>
          <year>2002</year>
          <fpage>552</fpage>
          <lpage>557</lpage>
          <pub-id pub-id-type="pmid">12196135</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0645">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weir</surname>
              <given-names>D.G.</given-names>
            </name>
            <name>
              <surname>Molloy</surname>
              <given-names>A.M.</given-names>
            </name>
          </person-group>
          <article-title>Microvascular disease and dementia in the elderly, are they related to hyperhomocysteinemia?</article-title>
          <source>Am. J. Clin. Nutr.</source>
          <volume>71</volume>
          <year>2000</year>
          <fpage>859</fpage>
          <lpage>860</lpage>
          <pub-id pub-id-type="pmid">10731489</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0650">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wellington</surname>
              <given-names>C.L.</given-names>
            </name>
          </person-group>
          <article-title>Cholesterol at the crossroads: Alzheimer's disease and lipid metabolism</article-title>
          <source>Clin. Genet.</source>
          <volume>66</volume>
          <year>2004</year>
          <fpage>1</fpage>
          <lpage>16</lpage>
          <pub-id pub-id-type="pmid">15200500</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0655">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wenk</surname>
              <given-names>G.L.</given-names>
            </name>
            <name>
              <surname>McGann</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Mencarelli</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Hauss-Wegrzyniak</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Soldato</surname>
              <given-names>P.D.</given-names>
            </name>
            <name>
              <surname>Fiorucci</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms to prevent the toxicity of chronic neuroinflammation on forebrain cholinergic neurons</article-title>
          <source>Eur. J. Pharmacol.</source>
          <volume>402</volume>
          <year>2000</year>
          <fpage>77</fpage>
          <lpage>85</lpage>
          <pub-id pub-id-type="pmid">10940360</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0660">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wenk</surname>
              <given-names>G.L.</given-names>
            </name>
            <name>
              <surname>McGann</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Hauss-Wegrzyniak</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Rosi</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>The toxicity of tumor necrosis factor-alpha upon cholinergic neurons within the nucleus basalis and the role of norepinephrine in the regulation of inflammation, implications for Alzheimer's diseaseAD</article-title>
          <source>Neuroscience</source>
          <volume>121</volume>
          <year>2003</year>
          <fpage>719</fpage>
          <lpage>729</lpage>
          <pub-id pub-id-type="pmid">14568031</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0665">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Whitehouse</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>Hedreen</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>C.L.</given-names>
              <suffix>III</suffix>
            </name>
            <name>
              <surname>Price</surname>
              <given-names>D.L.</given-names>
            </name>
          </person-group>
          <article-title>Basal forebrain neurons in the dementia of Parkinson's disease</article-title>
          <source>Ann. Neurol.</source>
          <volume>13</volume>
          <year>1983</year>
          <fpage>243</fpage>
          <lpage>248</lpage>
          <pub-id pub-id-type="pmid">6847136</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0670">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wilcock</surname>
              <given-names>G.K.</given-names>
            </name>
            <name>
              <surname>Esiri</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Bowen</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>C.C.</given-names>
            </name>
          </person-group>
          <article-title>Alzheimer's disease correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities</article-title>
          <source>J. Neurol. Sci.</source>
          <volume>57</volume>
          <year>1982</year>
          <fpage>407</fpage>
          <lpage>417</lpage>
          <pub-id pub-id-type="pmid">7161627</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0675">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wirths</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Multhaup</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Bayer</surname>
              <given-names>T.A.</given-names>
            </name>
          </person-group>
          <article-title>A modified beta-amyloid hypothesis: intraneuronal accumulation of beta-amyloid peptide &#x2014; the first step of a fatal cascade</article-title>
          <source>J. Neurochem.</source>
          <volume>91</volume>
          <year>2004</year>
          <fpage>513</fpage>
          <lpage>520</lpage>
          <pub-id pub-id-type="pmid">15485483</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0680">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wolozin</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Cholesterol and the biology of Alzheimer's disease AD</article-title>
          <source>Neuron</source>
          <volume>41</volume>
          <year>2004</year>
          <fpage>7</fpage>
          <lpage>10</lpage>
          <pub-id pub-id-type="pmid">14715130</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0685">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wood</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Alzheimer disease: fibrinogen links amyloid with vascular dysfunction</article-title>
          <source>Nat. Rev. Neurosci.</source>
          <volume>6</volume>
          <year>2010</year>
          <fpage>413</fpage>
        </element-citation>
      </ref>
      <ref id="bb0690">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhou</surname>
              <given-names>D.H.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>J.Y.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Deng</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Study on frequency and predictors of dementia after ischemic stroke, the cChongqing stroke study</article-title>
          <source>J. Neurol.</source>
          <volume>251</volume>
          <year>2004</year>
          <fpage>421</fpage>
          <lpage>427</lpage>
          <pub-id pub-id-type="pmid">15083286</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0695">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhu</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Perry</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Aliev</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Mitochondrial failure in Alzheimer's disease</article-title>
          <source>Am. J. Alzheimers Dis. Demen.</source>
          <volume>19</volume>
          <year>2004</year>
          <fpage>345</fpage>
          <lpage>352</lpage>
        </element-citation>
      </ref>
      <ref id="bb0700">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zlokovic</surname>
              <given-names>B.V.</given-names>
            </name>
          </person-group>
          <article-title>Clearing amyloid through the blood-brain barrier</article-title>
          <source>J. Neurochem.</source>
          <volume>89</volume>
          <year>2004</year>
          <fpage>807</fpage>
          <lpage>811</lpage>
          <pub-id pub-id-type="pmid">15140180</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0705">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zlokovic</surname>
              <given-names>B.V.</given-names>
            </name>
          </person-group>
          <article-title>Neurovascular mechanisms of Alzheimer&#xB4;'s neurodegeneration</article-title>
          <source>Trends Neurosci.</source>
          <volume>28</volume>
          <year>2005</year>
          <fpage>202</fpage>
          <lpage>208</lpage>
          <pub-id pub-id-type="pmid">15808355</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <ack>
      <title>Acknowledgements</title>
      <p>This study was supported by the Austrian Science Funds (L-429-B05).</p>
    </ack>
  </back>
  <floats-group>
    <fig id="f0005">
      <label>Fig.&#xA0;1</label>
      <caption>
        <p>A common unifying hypothesis for Alzheimer's disease. It is hypothesized that chronic mild exposure of different (vascular) risk factors may play a role in the development of Alzheimers disease. These factors are e.g. hyperhomocysteinemia, hypercholesterolemia or type 2 diabetes. This leads to damage of the neurovascular brain capillaries leading to silent strokes and acidic conditions (1) or to a dysregulation of &#x3B2;-amyloid at the blood-brain barrier resulting in increased &#x3B2;-amyloid (1&#x2013;42) levels in the brain (2). The cerebrovascular dysfunction may result in a damage of the sensitive neurovascular unit (3). The subsequent retrograde-induced cell death of cholinergic neurons correlates with the lack of cortical or hippocampal acetylcholine (4). Metabolic disturbances (e.g. enhanced influx of toxic compounds, reduced efflux of metabolic waste, or reduced energy supply) may induce neuroinflammation (5) and microglial activation and reactive gliosis (6). Different risk factors (such as metals, reduced pH, reduced transport or degradation of &#x3B2;-amyloid) may result in aggregation of beta-amyloid and plaque deposition (7). The cerebrovascular damage and dysfunctional &#x3B2;-amyloid clearance result in deposition of &#x3B2;-amyloid (angiopathy) in brain vessels (8). It is suggested that metabolic disturbances cause an imbalance of specific protein kinases (PK) or phosphatases (PP), resulting in abnormal tau phosphorylation, which finally cause the tau pathology (9). Microglia inflammation enhances matrix metalloproteinase-9 (MMP9) and cause a dysfunction of the metabolism of nerve growth factor (NGF) with a reduced bioavailability for cholinergic neurons, supporting their cell death (10). Tau pathology may on the other hand also be caused by &#x3B2;-amyloid plaque deposition (11) or may contribute to neuronal cell death (12).</p>
      </caption>
      <graphic xlink:href="gr1"/>
    </fig>
  </floats-group>
</article>
